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Pharmaceutical care as a health care service has already made its mark and been shown to 
make an important contribution to the health care system. However, there is still a demand 
from the NHS among others,  that pharmacist to a greater extent must document their 
provision of pharmaceutical care. Tested out in this project, is the application of a Care Issue 
Categorisation System.    
 
Aims 
To compare two clinical settings in terms of the profile of pharmaceutical care delivered and 
the profile of medication use. The findings will be reported in a way which allows quantitative 
comparison of pharmaceutical care issues addressed by the clinical pharmacy service in a 
proposed reporting, and a modified categorisation system will be use to accomplish this. 
 
Method 
A literature review were performed on pharmaceutical care, medicines management, 
common chronic diseases etc. Process maps were produced to describe the delivery of 
pharmaceutical care at the General Medical Ward at Glasgow Royal Infirmary. An existing 
categorisation system was modified and a guideline developed and both used for the 
analysis of documentation made by the pharmacists. Inter rater agreement on the 




The existing categorisation system was modified in several parts and tested by four 
investigators. Process  maps and analysis of the care issues documented reveal that there 
was a inconsistency between the pharmacist’s provision of care and documentation. The 




The modified categorisation system is tool that has the potential to aid future documentation 
of pharmaceutical provision of patient care. 
Comparison of pharmaceutical care activity between two ward showed that pharmacists are 
contribution to pharmaceutical care but that there are differences in their priorities and 
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Many lifesaving medicines work in a way that too much or too little can be the 
difference between successful treatment, unsuccessful treatment or toxicity. It is 
because of the recognised need to help patients get the most benefit from their 
medicines, and to minimise the associated risk, that the practice of pharmaceutical 
care have become increasingly meaningful.    
 
After the suggestion, by the UK government, through the NHS in 2000, of 
implementing medicines management services 1, pharmacists and technicians have 
to an ever-increasing extent found their rightful roles, and are becoming an 
increasingly important part of the health care team in hospitals. 
 
Pharmaceutical care as a health care service has already made its mark and been 
shown to make an important contribution to the health care system. However, there is 
still a need to continuously improve the work that is done. Among the elements that 
need to be addressed, are the ways in which pharmacists document their work. 
Although there are guidelines in how to perform pharmaceutical care, there is no 
doubt that there is great variety in how pharmacists proceed. In order to review and 
analyse the work carried out by pharmacists in pharmaceutical care practice, it would 
be advantageous that the documentation of the work in different settings is done in a 
similar, and therefore a standardised way. One way to make this happen is to have 
an organised, and well-functioned care plan. This should be designed in a way that 
easily shows what the pharmacists is implementing and contributing towards 
inpatient care. Tested out in this project, is the application of a Care Issue 










1.2 Pharmaceutical Care  
Over the past four decades there has been a clear tendency for pharmacy practice to 
extend its line from the original medicine supply, towards that involving a 
comprehensive focus on patient care. The pharmacist’s role has consequently 
evolved from that of a compounder and supplier of pharmaceutical products, to that 
of provider of patient care. 
 
The practice of Clinical Pharmacy can be defines as “…a discipline concerned with 
the application of pharmaceutical expertise to help maximise drug efficacy and 
minimise drug toxicity in individual patients.” 2 Pharmaceutical care is used to refer to 
the pharmacist’s contribution to patient care resulting from the practice of clinical 
pharmacy. 2 
 
This expansion to patient centred care comprises a new responsibility for the 
pharmacist, and that is to ensure the effectiveness and safety of a patient’s drug 
treatment in the best possible way. By providing patients with counselling, drug 
information and to monitoring their drug therapy, the pharmacist can make a vital 
contribution to the outcome of drug therapy and to the patients’ quality of life.3  
 
The most generally accepted philosophy of Pharmaceutical Care was defined in 1990 
by Hepler and Strand as;  
“The responsible provision of drug therapy for the purposes of achieving definite 
outcome that improve a patient’s quality of life”. 4 
The International Pharmaceutical Federation (FIP) adopted this definition in 1998 but 
added one amendment:  “…achieving definite outcomes that improve or maintain a 
patient’s quality of life”. 3 The definition has been redefined later by Cipolle, Strand 
and Morley; “Pharmaceutical care is a patient-centred practice in which the 
practitioner assumes responsibility for a patient’s drug related needs and is held 
accountable for this commitment ” 5 
 
These concepts of pharmaceutical care describe what the patient deserves to receive 
from care. However it doesn’t mention the pharmacist’s role in particular. Because of 
this fact, pharmaceutical care is open as a team responsibility involving a group of 
health care professionals and it can be delivered in different ways and settings. The 
term is in general referring to quality of medicines use and the focus is on achieving 
 11
the best outcomes for the patients by assuring optimal drug therapy. The Scottish 
Executives have further stated in their report “The Right Medicine – a Strategy for 
Pharmaceutical Care in Scotland: ”Pharmaceutical care reflects a systematic 
approach that makes sure that the patient gets the right medicines, in the right dose, 
at the right time and for the right reasons.” 6 The pharmacist’s role in this patient- 
care process is to determent whether the patients drug-related needs are met by 
taking responsibilities for these latter actions . 7 
 
In Scotland pharmaceutical care, through the practice of clinical pharmacy, has 
evolved trough gradually steps taken during the last 30 years. The development 
started with the “Aberdeen system” for prescription and administration recording, and 
went further with ward pharmacy and drug information services, to modern clinical 
pharmacy practice as we now it today. 2  
 
As pharmaceutical care has infiltrated the health care system, one can see that many 
different definitions and meanings of the term have been presented. In spite of this, 
there is one principal counting for all; the patient is the main focus and the 
responsibility lies in optimising his/her drug therapy. 
 
1.3 Medicines management  
 
Medicines management has been adopted rather than pharmaceutical care by the 
Department of Health in England and Wales. And although the terms are related they 
are not quite synonymous.8  
Medicines management comprises the initiatives to improve the means of the supply 
and use of medicines. 7 It describes how the work and collaboration between health 
care professionals (physician, nurse, technicians and pharmacist etc) can be 
organised to achieve and deliver pharmaceutical care and hence best outcome for 
the patients. 
 
In their report “A Spoonful of Sugar – Medicines Management in the NHS ”The Audit 
Commission defines; ”Medicines management in hospitals encompasses the entire 
way that medicines are selected, procured, delivered, prescribed, administered and 
reviewed to optimise the contribution that medicines make to producing informed and 
desired outcomes of patient care” 1 
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The purpose of medicines management is to optimise the way that medicines are 
used, both by individual patients and the National Health Service (NHS), and this is 
done by a wide range of activities. “Medicines management services are processes 
based on patient need that are used to design, implement deliver and monitor 
patient-focused care.” 1The services include all aspects of the supply and use of 
medicines, that is, from a patient’s medication review to a health promotion 
programme. Risk management (e.g. reducing errors caused by prescribed 
medicines) and disease prevention strategies (e.g. immunisation) are ways in which 
medicines management services are improving the health of the public. 1 
 
Several studies over the last few years have shown that pharmacists make a 
contribution in improving patient care as member of the health care team providing 
medicines management service, although there is emphasised that more research is 
needed with larger sample sizes and more areas, to better understand the role of the 
clinical pharmacist. Reduced medication errors, improved accuracy of drug history 
documentation, reduced prescribing costs, decreasing the potential risk to patients 
and patient discharge counselling, are among variables that have been tested and 
where it have been shown that pharmacists contribute to improvement and positive 
outcomes.1, 4, 8-10 
 
1.3.1 Why do we need pharmaceutical care and medicines management? 
 
The most frequently used form of treatment in any health care setting is drug therapy. 
The use of medicines has grown substantially as the population has aged and the 
prevalence of chronic diseases has proliferated.3 Also new “life-style 
medicines/ailments” and an increasing amount of over-the-counter drugs (OTC) have 
been marketed in the recent decades and to an ever increasing extent. This gives 
reasons for why pharmacists, in particular, have an important contribution to make by 
giving information about use and effects of these drugs, not just to inpatients but to 
all patients and the public in general. However, this report will further focus on 
situations occurring in the hospital setting, where the latter account for a smaller part 
of the larger picture.  
There are several reasons why pharmaceutical care and medicines management are 
needed in hospital; 
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With today’s exploding development in new drugs, ensuring the safe and effective 
use of the medicines is a complex and growing challenge. Due to the ageing 
population with multiple diseases and polypharmacy, combined with advanced drug 
regimens, patients may have difficulties managing their own drug regimens.1, 11 
Issues that need to be addressed here are for one the fact that up to 50% of patients 
(especially the elderly) do not or cannot take their medicines as prescribed. Some 6-
17% of older inpatients experience some kind of adverse drug reactions while in 
hospital, and drug related problems are implicated in 5-17% of actual hospital 
admission in this group. 12  
 
Unintentional changes in medication after discharge from hospital are a common risk. 
The prescriber not having the immediate access to accurate information about either 
the medicine or the patient, causes most errors. Hand-written prescriptions or 
patients notes also contribute to errors, as they may be illegible, incomplete, subject 
to transcription errors or using inappropriate abbreviations. 1 Continuing the 
implementation of Medicines Management can improve this lack of good 
communication between health care personnel. 6 
 
It must also be kept in mind the importance of assuring the most rational use of 
medicines. This implies the need to ensure that patients receive the appropriate drug 
for their clinical needs, in the doses that are effective and safe for each individual, for 
an appropriate period of time and at the most economical cost possible for both them 
and the community 3.  
 
All these examples of contributions emphasise the importance of Medicines 
Management and the collaboration between different health care personnel. 
Pharmaceutical care in terms of evaluating and monitoring drug regimens, informing 
the patient about medicines effect and use, and the follow-up of the patient are also 
of obvious importance here. There is no doubt that when medicines are used for the 
greatest possible benefit of each individual patient, and of society as a whole, this will 






1.4 The hospital pharmacist specialisation.  
 
There has been a great development over the past 30 years in both the role of the 
pharmacist as carer for patient and in the general knowledge about diseases and 
drugs. This has led to a significant vigilance where it has been realised that the 
traditional roles of the physician prescribing and the pharmacist dispensing is no 
longer sufficient to ensure the safety, effectiveness and compliance to drug therapy.  
Errors related to medicines use are costly for the domestic economy in terms of 
hospitalisations, laboratory tests and remedial therapy 3 
 
To an ever-increasing extent the impact drug therapy can have on patient care has 
been made visible; interaction, administration problems, adverse drug reactions, 
compliance and educational needs. This has led to the opening and widening of the 
need for clinical pharmacists to improve the use of medicines. Due to the increasing 
complexity of drug therapy management, pharmacists have established clearer roles 
in the health care team, optimising the patient drug therapy by identifying and 
resolving drug therapy problems and preventing new problems from occurring. 1, 5, 6 
In UK the last twenty years, hospital pharmaceutical services have had a 
considerably development with clinical pharmacy services being established as an 
important part of hospital healthcare. Through the practice of clinical pharmacy the 
pharmacists provide services intended to deliver pharmaceutical care to hospital 
patients.13, 14 
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1.5 Pharmaceutical Care Issues and Drug Therapy Problems  
 
The pharmacist initiates his/her provision to pharmaceutical care by gathering 
information about the patient’s drug treatment and medical history. Through an 
assessment, pharmaceutical care issues will be revealed.  
A pharmaceutical care issue is an identified concern regarding a potential or actual 
drug therapy problem which is addressed by the pharmacist.  
When a patient’s drug related needs are not being met they usually result in drug 
therapy problems. (DTPs) 
 
“A drug therapy problem is any undesirable event experienced by a patient which 
involves, or is suspected to involve, drug therapy and that interferes with achieving 
the desired goals of therapy” 5 
 
The most common cause of adverse incidents in hospital patient is a complication 
arising from the use of medicines. The drug-related problems may be caused due to 
the effect of the drug, patient factors or other idiosyncratic factors. The way in which 
drugs are administered will also make an impact and might be a contributing factor. 11  
Cipolle, Strand and Morley have stated that: ” Identifying drug therapy problems is to 
pharmaceutical care what making a medical diagnosis is to medical care”, 5 in other 
words, the most important contribution the pharmacist can make. And further to take 
the responsibility to resolve and prevent them.  
 
 
1.6 Pharmaceutical care provided by the hospital pharmacist.  
 
In the absence of a standard description of pharmaceutical care, or consistent level 
of staffing in the NHS, different hospitals and primary care services have adopted 
different levels of care provision. (ref bok R) 
 
The American Society of Health-System Pharmacists, ASHP published a document 
in 1996 15 where they presented guidelines on a standardised method for 
pharmacists providing pharmaceutical care. Their document described a method 
based on function that they thought all pharmacists should perform for individual 
patients in organised health systems. The reason for this was the recognition of 
considerable variation in pharmacists’ provision of pharmaceutical care. With a 
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standardised method it would be a consistency in the provision of pharmaceutical 
care in any practice setting. The aim with these guidelines was among many to assist 
pharmacists in implementing pharmaceutical care in their work sites. Also that these 
methods would establish consistent documentation so that information concerning 
the patient and his/her drugs could be shared between pharmacists and other health 
care personnel. Following are the points which the ASHP believed should be 
included in the standardises methods of pharmaceutical care;   
 
- Collecting and organising patient-specific information, 
- Determining the presence of medication-therapy problems,  
- Summarising patients’ health care needs, 
 
- Specifying pharmacotherapeutic goals, 
- Designing a monitoring plan, 
- Developing a pharmacotherapeutic regimen and corresponding monitoring plan 
in collaboration with the patient and other health professionals, 
 
- Initiating the pharmacotherapeutic regimen, 
- Monitoring the effects of the pharmacotherapeutic regimen, and 
- Redesigning the pharmacotherapeutic regimen and monitoring plan15 
 
Today it points to that this standardised method is implemented among the 
pharmacists in different degree and manners in the clinical settings. 
As emphasised, the pharmacist is a member of a health care team providing 
pharmaceutical care. The pharmacist’s task and hence responsibility in the delivery 
of pharmaceutical care, if first and foremost to ensure safety and effectiveness 
regarding the patient drug therapy. This means to ensure that a patient is given 
drug(s) that is appropriately indicated, the most effective available, the safest 
possible, and most convenient for the patient.  3 
 
The pharmacist’s contribution can further be divided into 3 main processes in order to 
fulfil this accountability; 
1. Identifying potential and actual drug therapy problems 
2. Resolving actual drug therapy problem 
3. Preventing potential drug therapy problems.6, 8  
 
There are many ways in which all of these tasks can be performed, depending on the 
individual situation of each patient. However, they all involve assessment, monitoring 
and follow-up of the patients in order to be accomplished. Assessment is a key word 
in the approach to patient care, and means in this setting “the identification and 
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review of an individual patient’s pharmaceutical care issues”. 2 The assessment 
comprises medication history, evaluating prescribed drugs, monitoring drug therapy, 
consulting clinical records and liaising with the patient, carer and other health care 
members 2 
 
As a general there are however some important points regarding these 3 main 
processes: 
Identifying a drug therapy problem requires the pharmacist to spot the association 
between a patient medical condition (signs, symptoms, abnormality etc), physical 
condition (e.g. allergy etc) and his/her drug therapy.  
Resolving a drug therapy problem requires the pharmacist to know how, or be able to 
find out how, to deal with the unmet needs of the patients’ drug therapy and disease 
state. This most often involve a discussion and cooperation with other health care 
members. 
Preventing drug therapy problems is also a major task for the pharmacist. When it 
comes to drug therapy it is important that the patient receive appropriate preventive 
medications if necessary. (e.g. aspirin to prevent myocardial infarct in high risk 
patient) 5 Also assuring that the patient  does not receive any medicines which cause 
interaction, side-effects or are contraindicated etc. are part of the prevention of drug 
therapy problems. 
 
Moreover, the pharmacist plays an important role in ensuring that the patient gets the 
information they need and understands how to use their medicines and by this have 
the best starting point to achieve the best outcome. In addition monitoring of drug 
therapy, general patient education and follow-up of the patient, in order to ensure the 
best therapeutic outcomes, are also all included in the preceding processes. All 
together these are contributions to pharmaceutical care made by the pharmacists on 
the wards.  
 
A more detailed description of how the different tasks are performed will be described 






1.7 Categories of Drug Therapy Problems  
 
It was in 1990 that a research group at the Peters Institute of Pharmaceutical Care at 
the University of Minnesota defined and developed the categorisation of drug therapy 
problems 5 The research group categorised patient problems involving medication 
into 7 different types of drug therapy problems. (Table1) The same classification of 
drug therapy problems, with small adjustments, will be used in this project. The 
categories are adopted from the book “Pharmaceutical Care Practice – the Clinician’s 
guide”.5 All together these seven categories sum up the problems that drugs might 
cause, but also how drugs can solve them; by changing and optimise the drug 
therapy.  
 
Table 1.Categories of drug Therapy Problems5 
Drug Therapy Problem DTP 
Unnecessary Drug therapy DTP 1 
Needs additional drug therapy DTP 2 
Ineffective drug product DTP 3 
Dosage too low DTP 4 
Adverse drug reaction DTP 5 
Dosage too high DTP 6 
Non-compliance DTP 7 
 
Looking at the different drug therapy problems one can see that they also cover the 
four aspects of indication, effectiveness, safety and compliance (table 2).  




 Unnecessary Drug therapy 





 Ineffective drug product 





 Adverse drug reaction 








For further details on the subcategories of the DTP see Appendix and “Guidelines – 
Suggested Categorisation for Pharmaceutical Care Issues” 
 
1.8 Why categorise Drug Therapy Problems? 
 
The Guideline – “Suggested Categorisation for Pharmaceutical Care Issues” will 
describe the process of categorising care issues into different categories, a 
triangularised system. Following are a sum up of why Drug Therapy Problems are 
divided into 7 different categories. 
 
Drug therapy problem encompasses the drug, the patient and the medical problem 
that links them together. Despite the fact that there is a huge number of different 
drugs and prescriptions, and quite a number of acute and chronic diseases, which 
theoretically could have given unmanageable numbers of drug therapy problems, 
there are only seven main groups of drug therapy problems. 5 
 
Categorising drug therapy problems into these different categories is advantageous 
for many reasons.  With different categories, a systematic process of problem solving 
can be developed and aid the pharmacist in obtaining the overall positive health 
outcomes of each individual patient. And by this, ease the work done by pharmacist 
in pharmaceutical care. On a population level the categorisation of DTP could help 
pharmacoepidemiologists in developing a national database concerning DTPs and 
make the documentation clearer. 5 
 
Make sure all new paragraphs have a line space to clearly separate them 
Furthermore, these categories will help to clarify the professional responsibilities of 
the pharmacist working with pharmaceutical care as a team member. Dividing DTP 
into different categories put care issues, such as noncompliance, into a visible clinical 
perspective. Another function of this categorisation is that it gives the pharmacist a 
vocabulary that coincides with that used by other health care professionals. By 
defining the pharmacist’s function in terms of identification, resolution and prevention 
of DTP, his/her function is placed in a patient-care context consistent with the 






1.9 The Care Plan 
 
In Scotland, many pharmacists in the hospitals are trained and encouraged to 
provide a care plan for patients in their care. The care plan will state the care issues 
regarding the patient medical condition(s) and drug therapy. A planned action to be 
taken, together with the outcome of the former, should also be included in the care 
plan.  
 
“The concept of a pharmaceutical care plan is the use of a document as a clinical tool 
that identifies potential problems with a patient’s medicines. It records the 
pharmacist’s action with patients, nurses and doctors to address those problems.“ 7  
 
The main purpose of the care plan is, in co-operation with the patient, to determine 
how to best manage his/her medical conditions in the best way by using drug 
therapy.5 The documentation within the care plan first of all points out the desired 
outcome of the patient’s drug therapy and describes the actions taken to accomplish 
this.  By committing to writing the care issues addresses by the pharmacist in the 
care plan the work done is validated, and hence the care plans can be assigned a 
“quality assurance document”. 14 The monitoring and follow-up of the patient is also 
an important part of the pharmaceutical care, which should be included within the 
care plan to determine the outcomes of the drug treatment at a clinically appropriate 
time.  
 
As mentioned at the beginning, the care plan has a standard template in general, but 
how it is used and how the documentation is performed differs widely among the 
individual pharmacists. This can probably not be avoided, but by improving the 
documentation by making it more consistence, clearer and hence valuable for other 
health care member, this could result in a tool for better continuity of care between 
secondary and primary settings. 
 
1.10 Documentation in pharmaceutical care - amendment ahead 
 
Compared to the pharmacists’ traditional role, the practice of pharmaceutical care still 
needs to continue finding its way and become recognised. For the time being 
pharmacists have not to a considerable extent undertaken the responsibility to 
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document, monitor and review the care they are giving. Nonetheless, accepting to do 
this is essential to the practice of pharmaceutical care. 6, 7 
 
In the review article “ The Changing role of pharmacists in society ” there is a stated 
demand for pharmacists taking action in helping improving the system that they are 
working in by, among other things, documenting problem solving, improving 
teamwork and continuity of care. 7 Also the Scottish Executive has stated in their 
report  “The Right Medicine. A strategy for pharmaceutical care in Scotland” that the 
actions the pharmacist performs in clinical health care, needs to be recorded in order 
to develop and ensure the improvements in pharmaceutical care in Scotland.6 Most 
reports and document guidance today regarding documentations is made for the 
community pharmacy systems. However, it is emphasized in the recent document 
from the Royal Pharmaceutical Society of Great Britain – “Guidance on Recording 
Interventions”, that documentation on the actions pharmacist perform applies equally 
to wherever a pharmacist practices. 16  
 
 
1.10.1 Why is documentation important? 
 
As continuity of care and good communication between health care personnel within 
and between clinical settings are key elements in good pharmaceutical care practice, 
this would depend on reliable records. 16 
 
The Royal Pharmaceutical Society of Great Britain implies several reasons why 
pharmacist should make an effort to document the work they are doing. Firstly, to 
ensure patient safety and to improve the quality and continuity of care. Secondly to 
have an accurate document available on closer inspection when decisions made 
regarding a patient are questioned (e.g. changes made in prescribing). By 
documenting the contribution and actions made by pharmacists in the health care 
services, evidence of the value a pharmacist represents as a member of the health 
care team, is also identified (e.g. improvement in patient care through their clinical 
input to patient assessment) 16 
 
Documentation further points out the extent of responsibility the pharmacists have 
taken for their professional actions and is an important component in demonstrating 
how professional judgement is put into practice. Moreover it is emphasized that any 
situation where the pharmacist makes a significant contribution to patient care should 
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be included in the documentation, not only prescription interventions. These 
situations would, among others, include alterations that are of clinical significance 
and could be regarded as having direct impact on patient care, and alterations that 
lead to learning and improvement of standards of care. 16  
 
By making a standard way of documenting their identification of care issues and 
problem solving, pharmacists will also have to be aware of what kind of action they 
are taking in the care plans. Whether they are making an impact on the patient 
behaviour or the drug therapy etc. The suggestion in this research project to 
categorise the different care issues into Check or Changes categories (Strand, 
McAnaw)17, Drug Therapy Problems (Cipolle, Strand)5, and Quality Assurance 
Descriptors (McAnaw, Hudson)7 will also make it clearer for the pharmacist and 
others interested, what exactly is happening in the care plan. In other words, what the 
pharmacist is identifying, resolving and preventing in the patient’s drug therapy will be 
made visible, and also when in the treatment cycle it is done.  (see Appendix 2)    
 
 
1.11 The General Medical Ward 
 
The General Medical Ward at the Glasgow Royal Infirmary, is also known as the 
Cardiac and Diabetic ward. Patients are admitted to this unit either directly from 
referral from the Acute Receiving Unit, the Coronary Care Unit (CCU), from the 
diabetic clinics or after a planned admission that have come via a GP referral to a 
hospital internal specialist. In general the patients admitted here suffer from different 
diseases. Most of them have some form of cardiovascular complication, alone or in 
addition to other diseases and internal medicine exacerbations. Many of the patients 
at this ward are transferred further to other wards for continuity of care. 
 
The pharmacist at the General Medical Ward works as a member of the health care 
team. The responsibilities of the pharmacist lie in checking and optimising the 
patients’ drug therapy to ensure safe and effective use of medicines for the patients 
at this ward. Further description of the tasks performed by the pharmacist will be 




1.12 Comorbidity and Complications – reasons for acute exacerbation  
 
The term “co-morbidity” means that more than one illness affects an individual, and 
that each of the illnesses may influence the course and management of the others. 18 
Those who suffer multiple illnesses often suffer them simultaneously. Each condition 
can seldom be treated in isolation from the others. There has been recognised an 
urgent need to know much more about the optimal management of patients with 
comorbidity. Their complex needs lead to greater dependence on hospital stay to 
support them. Joint working between primary and secondary healthcare teams can 
be one way to best achieve this.18   
 
1.13 Chronic disease management and hospitalisation 
Chronic disease is a condition that last 3 months or longer and requires ongoing 
medical care. 19 As people live longer the prevalence of chronic diseases are 
increasing. The modern healthcare has realised that responding well to the needs of 
these patients is important in order to optimise their quality of life and prevent future 
burden both for the patients and the health services.  
 
A definition of chronic disease management is: “A system of coordinated healthcare 
interventions and communications for populations with long-term conditions in which 
patient self-care is significant.”18 
 
Chronic diseases include diabetes, asthma, arthritis, heart diseases, depression, 
psoriasis etc. Their degree and severity vary, but for many these conditions have a 
great impact on a person’s life. Chronic diseases of different kind are reported in 
about 60% of adults.  The Department of Health stated in 2004 that people with 
chronic diseases are significantly more likely to see their GP, as they account for 
about 80 % of GP consultations.  On average they are admitted as an inpatient twice 
as often, and stay in hospital longer than people without chronic disease. Moreover, 
15% of people with three or more problems account for 30% of inpatient days. 20 
 
The NHS Improvement Plan in 2004 highlighted the need for effective management 
of chronic diseases as a national priority to provide better services and quality care 
for patient with long-term conditions. The aims is both to enhance benefits for the 
patients but also to create a more efficient health service that would be able to meet 
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the needs for all the patients it serves.21 There is strong evidence that improved 
management of these conditions would lead to fewer admissions to hospitals/ 
inpatient care. By slowing the progression of a disease this can delay and prevent 
the need for treatment in hospital. For example, better management of high blood 
pressure and high cholesterol in patients with heart disease means that fewer of 
these patients will be readmitted with heart failure and require heart surgery.20  Most 
of the interventions aimed at the managing and preventing of chronic diseases are 
delivered in the primary and community settings. However an effective approach to 
chronic management requires a system that works across primary and secondary 
care and social services as an integrated system. 19, 20 
 
Further, the Department of Health emphasises that ” improving approaches to 
chronic disease management is not just an issue for primary care organisations, but 
will also impact on secondary and emergency care through: reducing waiting lists; 
improved management of demand; development of the workforce; improved 
medicines management; and freeing up resources to improve other services.” 19. By 
achieving these outputs it is expected that quality of care and health outcomes for 
patients will be improved. 19  
 
Health promotion that is focused on preventing the wider population from developing 
chronic disease is also of huge importance in containing the prevalence of chronic 
disease. 19 In relevance to the General Medical ward, high alcohol intake, obesity and 
smoking are risk factors for both diabetes and cardiovascular disease. These are 
concerns, which mainly are dealt with in primary care based services through GP and 
specialist practice nurses and practice pharmacists (primary care pharmacists). Still 
there is connection to secondary care through continuity of care, by referring 
inpatients with these problems to smoking cassation, health counsellors and 
outpatient clinics etc. and provide them with necessary information and education 








1.14 Diseases on the General Medical Ward 
 
Since 59 % of the patient at the General Medical Ward during the survey period 
suffered from cardiovascular disease and 17% had the diagnosis diabetes mellitus, 
the comorbidity of these chronic diseases will be reviewed. The complication arising 
from diabetes mellitus will also be presented.  
 
1.14.1 Diabetes mellitus 
 
Epidemiology and aetiology 
Diabetes Mellitus is among the most common chronic disorders in the UK. It is 
characterised by varying degrees of insulin hyposecretion and/or insulin insensitivity 
and associated with hyperglycaemia. The two main types of diabetes mellitus are 
type 1 and type 2. Type 2 is the most common affecting approximately 75% of all 
patient with the disease in most populations. It usually occurs in patients over the age 
of 40 years and the incidence of type 2 increases with age and with increasing 
obesity. Type 1 may present at any age but there approximately 50-60% present 
before 20 years of age. The aetiology differs between the two types. In short; with 
type 1 the β cells in pancreas are destroyed due to autoimmune or idiosyncratic 
reasons. This usually leads to absolute insulin deficiency. With type 2 there is a 
decreased production of insulin and/or an insulin resistance. 22  
 
Approximately 3.5% of the population the UK suffer from diabetes mellitus (10 
percent from Type 1 and 90 percent from Type 2) and the prevalence is rising. 23 It is 
estimated that there will be three million people with diabetes in the UK by 2010. The 
potentially consequences for the health service will be increased workload and 
financial costs. The identification of diabetes and the importance of this to the health 
of the nation have been acknowledged by all four nations of the UK. It has been 
accepted that the primary care will be the organ that will provide the majority of 
routine clinical care for this patient group 24 Still, the hospital health care team have 
an important responsibility in ensuring safe and effective treatment of patients 
admitted with exacerbation of their diabetic disease, diabetes complicating a 





1.14.2  Complications of diabetes mellitus 
 
 
The initially treatment aims of diabetes mellitus are in general to relieve of the signs 
and symptoms of the disease. (polydipsia, polyuria, weight loss and ketoacidosis) 
However, since this is a chronically disease, in long-term the treatment aims would 
also be to prevent the development, or slow the progression of possible 
complications of the disease.25, 26 
The two controllable factors that influence the development of diabetic complications 
are persistent hyperglycaemia and hypertension. These can further be divided into 
those caused by microvascular disease and those secondary to macrovascular 
disease.22 These latter will briefly be presented in what follows. 
 
 
1.14.3  Microvascular diseases  
 
Microvascular disease refers to damages to the small blood vessels supplying the 




Retinopathy is one of the long-term complications the diabetic patients risk. It is 
caused by changes in the blood vessels of the retina. These changes can either be 
that the blood vessels are blocked, swell and leak fluid or that abnormal new blood 
vessels grow on the surface of the retina. If left untreated this damage vision, and in 
the working population diabetic retinopathy is the leading cause of blindness. To 
reduce the risk it is important to keep blood glucose, blood pressure and blood fat 
levels under control. People with diabetic should have their eyes screened every 
year. 26 28, 29 
 
1.14.3.2 Diabetic Neuropat 
 
Neuropathy causes damage to the nerves that transmit impulses to and from the 
brain and spinal cord, to the muscles, skin, blood vessels and other organs. 26 30 
Diabetic neuropathies are very heterogeneous and include focal neuropathies 
(entrapment syndromes and mononeuropathies), distal sensory polyneuropathy, and 




Diabetes is the most common cause of neuropathy in the Western world. A large 
cross-sectional study of 6487 diabetic patients in the UK found the prevalence of 
diabetic neuropathy to be 28.5%. The prevalence increased with the duration of the 
disease. The most common neuropathy was distal sensory polyneuropathy, with a 
prevalence of 54% in patients with type 1 diabetes, and 45% in patients with type 2 
diabetes. 31 Distal sensory polyneuropathy (“glove and stocking” sensory symptoms) 
is a length-dependent process, with the most distal portions of the longest nerves 
affected earliest.  Thus, the earliest symptoms typically involve the toes, and then 
ascend. The pain is particularly troubling to most patients, and it is common for such 
patients to present primarily because of pain in the feet.  It can be the most disabling 
of all diabetic complications, and is a cause of considerable morbidity. Distal sensory 
polyneuropathy also predisposes patients to neuropathic foot ulcer. Foot problems 
are the complication which accounts for the highest inpatient hospital bed occupancy 
in diabetic patients.22, 31 
 
Despite research, there is still no conclusive proof of what causes diabetic 
neuropathy. However both metabolic and vascular factors appear to be involved in 
the pathogenesis. Hyperglycaemia causes chemical changes in nerves that can 
impair their ability to transmit signals. Hyperglycaemia can also harm the blood 
vessels that carry oxygen and nutrients to the nerves. 26,31 The necessary way to 
diminish the risk of developing neuropathy, or prevent it becoming worse, is to control 
the blood glucose level. 30   
 
1.14.3.3  Nephropathy / kidney disease 
 
Nephropathy or kidney disease is a serious condition where the kidney becomes 
damaged and more protein than normal is excreted in the urine. Over time, the 
kidney’s ability to function begins to decline, which may eventually lead to chronic 
kidney failure and in the worst case end-stage renal disease. Diabetes is the major 
cause of kidney failure. 21, 22, 32 Like retinopathy and neuropathy, nephropathy is also 
caused by damage to the small blood vessels. 26 The earliest clinical evidence of 
nephropathy is called microalbuminuria and this is the appearance of low levels of 
albumin in the urine (30 mg/day). The overt nephropathy is urinary albumin excretion 
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of more than 300 mg per day. About 20-30% of patient with both types of diabetes 
develop evidence of nephropathy.  
 
The typical time frame for nephropathy to develop is 10 to 20 years after onset of 
diabetes mellitus. Elderly patients with diabetes are therefore at higher risk than 
younger patients at developing nephropathy, which progresses from 
microalbuminuria to overt proteinuria. Independent risk factors for proteinuria and 
renal insufficiency include poor glycaemic control over many years, hypertension, 
high serum total cholesterol levels, and smoking. 30 In addition to it being the earliest 
manifestation of nephropathy, albuminuria is a marker of greatly increased 
cardiovascular morbidity and mortality for patients with either type 1 or type 2 
diabetes. 25 
 
The Diabetes Control and Complications Trial (DCCT) and the United Kingdom 
Prospective Diabetes Study (UKPDS) have shown that intensive diabetes therapy 
can significantly reduce the risk of the development of microalbuminuria and overt 
nephropathy in people with diabetes.25 As the kidney is one of the major excretion 
pathways for drugs in the body it is essential to have the knowledge of which drugs 
are affected when the patient suffer from renal impairment. To spot the need for dose 
reductions or contraindications leading to a change in drug therapy are of very high 
importance in order to prevent serious adverse drug reaction and toxicity. 
 
The DCCT and the UKPDS studies further stated that prevention is the keyword in 
the management of microvascular diseases in general. Tight blood pressure control  
(average 140/88 mmHg) gave a reduction of 37% in microvascular disease, and an 
intensive blood glucose control (between 4 and 6 mmol/l before meals, and less than 
10 mmol/l two hours after a meal) decreased the risk of microvascular disease by 
25%. 25, 30, 33 
 
1.14.4 Macrovascular disease and diabetes mellitus 
 
Macrovascular disease refers to illnesses in the large blood vessels including the 
coronary arteries, the aorta, and the biggest arteries in the brain and in the limbs. A 
common term for the diseases which affect these arteries are cardiovascular 
diseases (CVD) and these include; ischemic heart disease (angina and heart attack), 
heart failure, stroke and all other diseases of the heart and circulation, such as 
 29
hardening and narrowing of the arteries supplying blood to the legs - peripheral 
vascular disease (PVD). This latter also account for much of the morbidity associated 
with foot problems among people with diabetes. Heart diseases and stroke are 
however the two most common forms of CVD.  22, 23, 27 
 
The risk of CVD is increased up to a fivefold in people with diabetes compared to 
those without diabetes. 23, 34, 35 Cardiovascular disease is also the major cause of 
both morbidity and mortality in people with diabetes, with coronary heart disease as 
the most common cause of death among people with diabetes type 2. 34, 36 The 
United Kingdom Prospective Diabetes Study (UKPDS) showed that an increase in 
HbA1c levels from 6% to 11% doubled the risk of myocardial infarction. 35 The reason 
for this is believed to be prolonged, poorly controlled blood glucose levels, which 
affect the lining of the body’s arterial walls.  As people with Type 2 diabetes often 
also have low level of HDL cholesterol and raised levels of triglycerides this further 
increases the likelihood of plaque and formation of atherosclerosis. In general raised 
blood lipid levels are known to be a risk factor for coronary heart disease and 
management of the lipid levels can contribute to the reduction in cardiovascular risk 
in people with type 2 diabetes 23,36 
 
Hypertension is another risk factor associated with many complications of diabetes, 
especially cardiovascular disease. General recommendations state that blood 
pressure in diabetic patients should be < 140/90 mm Hg or <130/85 mmHg.26, 33, 37 
Findings from the United Kingdom Prospective Diabetes Study (UKPDS) indicated 
that tight blood pressure control (average 144/82 mm Hg) reduced the risk 
significantly by 24 % for any end points related to diabetes. Heart failure and stroke 
achieved a reduction in risk of 56 % and 44 % respectively.33, 36  
 
At the Diabetes UK’s Annual Professional Conference in Glasgow in March 2008 
numbers from a ten years study was presented. It revealed that between April 2005 
and March 2006 people with diabetes accounted for 13.9 per cent of all hospital 
admissions for heart attacks compared to 7.2 per cent between April 1996 and March 
1997. Further the researchers studied hospital records for more than 2.8 million 
major cardiovascular events and over 600 000 cardiovascular procedures in England. 
From these findings there were shown that in the same two periods angina 
admissions more than doubled from 6.7 per cent to 15.3 per cent in people with type 
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2 diabetes. Stroke admissions increased from 6.1 per cent to 11.3 per cent as well. 
These results give rise to concerns, as 80 percent of people with diabetes die of CVD 
related complications each year. However it has been shown that good diabetes 
management can reduce the risk of heart disease by 56 per cent, 38  and it is of great 
importance that people with diabetes have good access to high-quality care to enable 
them to control their disease. This would include monitoring of blood lipid levels and 
blood pressure regularly. 36    
There is a range of other complications that can occur in diabetic patients. These 
include hypoglycaemia, diabetic ketoacidosis, non-ketotic hyperglycaemic coma, 
musculoskeletal problems and dermatological conditions. In addition it seems that 
many infections (e.g urinary tract infection) are seen more frequently in diabetes 
patient due to poor diabetic control 22, 26. 
General information and education around these diseases are important. 
Polypharmacy enhances the risk of adverse side effects, interactions, and 
nonadherence to taking drugs. These problems are increased in patients with 
comorbidity of diabetes and cardiovascular disease, in which several medications are 
necessary to manage hyperglycemia, hyperlipidemia, hypertension etc.30 
Assessment and follow-up need to be performed and undertaken both in primary - 
and secondary care, wherever the patients are. Continuity of care is thus essential in 
this setting. 
 
1.15 Non-medical prescribing   
 
The Health and Social Care Act 2001 gave permission for the introduction of 
independent and supplementary prescribing status for health care professionals, and 
this included community and hospital pharmacists.13  
Hence there are two types of prescribers to be recognised; 
The independent prescriber (doctor/ dentist) is responsible for the assessment and 
diagnosing of patients and decision about their clinical management, including 
prescribing. 
 
The supplementary prescriber (pharmacist or nurse) will be responsible for the 
continuing care of a patient who has been assessed by the independent prescriber. 
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This might include prescribing within clinical guidelines, repeating prescriptions and 
adjustment of dose or dosage form according to the patient’s needs. 39 
 
The definition of supplementary prescribing is “a voluntary partnership between an 
independent prescriber and a supplementary prescriber to implement an agreed 
patient–specific Clinical Management Plan with the patient’s agreement.” 40  This 
means that before supplementary prescribing can take place, it is mandatory for an 
agreed Clinical Management Plan CMP to be established (written or electronic). The 
plan will be developed to include the diagnosis of the patient by the doctor/dentist 
and followed by a consultation and an agreement between the independent and 
supplementary prescriber.40 The principle emphasised in the concept of 
supplementary prescribing is partnership. This include the patient, so in order to carry 
out this action it is required that an explanation of what supplementary prescribing 
entails is given to the patient and then the patient’s approval must be obtained. The 
CMP may include local or national clinical guidelines, as an alternative to listing 
medicines individually. It should though be emphasized that supplementary 
prescribing only will be undertaken as long as the pharmacist has the skills to 
perform this task. In order to become a supplementary prescriber the pharmacists 
must undertake a specific programme of preparation which standards are set by the 
Royal Pharmaceutical Society of great Britain (RPSGB) and approved by NHS 
Education for Scotland (NES) 39 
 
The supplementary prescribers responsibilities lies within monitoring and assessing 
the patient in accordance with the patient’s condition and medicines prescribed. The 
supplementary prescriber has influence on the choice of dosage, frequency, product 
and other variables in relation to medicines within the limits specified by the CMP. In 
order for the supplementary prescribing to be safe and effective it is essential that the 
relationship between the independent prescriber and the supplementary prescriber is 
based upon good communication where they agree and share a common 
understanding of the written CMP. They must share the same local or national 
guidelines or protocols if these are referred to in the CMP and consult each other 
when needed in the review of the patient. 39 
 
Supplementary prescribing is primarily intended for use in managing specific chronic 
diseases or health needs affecting the patient. Still, there are no legal restrictions on 
the clinical conditions that supplementary prescribers may treat, provided that they 
 32
are included in the CMP. Supplementary prescribers are able to prescribe all 
medicines with the current exceptions of Controlled Drugs and unlicensed drugs.39 
 
1.15.1 Aims of supplementary prescribing  
 
The Scottish Executive’s strategy document “The Right Medicine: A Strategy for 
Pharmaceutical Care in Scotland”, calls for joint working between medical and 
pharmacist practitioners. “Supplementary prescribing by pharmacists facilitates joint 
working, particularly between community pharmacists and GPs and hospital doctors 
and pharmacists by allowing registered medical and dental practitioners to better 
utilise pharmacists’ expertise for the benefit of patients.” 39  
 
The Department of Health defined that; “Supplementary prescribing is intended to 
provide patients with quicker and more efficient access to medicines, and to make 
the best use of the clinical skills of eligible professionals.” 41 The intention is further to 
improve the ongoing process of optimising the patient’s drug treatment. The 
supplementary prescribing is based upon the foregoing development of 
pharmaceutical care as a system for identifying, resolving and preventing drug 
therapy problems. The pharmacist is already taking part in the team process of 
pharmaceutical care by assessing the effectiveness and safety of drugs, monitoring 
and giving patient education etc. Fulfilling the care by being able to prescribe new 
medicines or altered doses, which the pharmacist himself recommends in the first 
place, ensures the follow-up by one health care member. It is however important to 
emphasise that there should be a dialogue and discussion between the pharmacist 
and the physician, or other health care members, when it comes to ensuring the best 
drug treatment for the patient, as pharmaceutical care is a health care team 
responsibility. The effectiveness of supplementary prescribing is in this regard to 
avoid unnecessary time spent by the physician on clerical which the pharmacist can 
do him/herself when the prescription is the result of an agreement between the two 
health professionals. The intention forward is that with time, supplementary 
prescribing is likely to reduce the doctor’s workloads, freeing up their time to 
concentrate on patients with more complicated conditions and treatments. 6, 13, 42 
“Time spent initially developing a simple Clinical Management Plan, is intended to be 
time saved when the patient returns for review to the supplementary prescriber rather 





1.16 Clinical Audit 
 
Audit is a system widely used in the UK. It is generally a term involving an 
evaluation/review of a product, process or system in order to spot areas which need 
to be improved or changed. 
 
Clinical audit was introduced to the NHS in the late 1990s. A Clinical Audit is defined 
as  “ a quality improvement process that seeks to improve patient care and outcomes 
through systematic review of care against explicit criteria and the implementation of 
change.” Clinical audit is used in a wide variety of topics and differs from clinical 
research in that clinical audit “…aims to establish the extent to which actual clinical 
practice compares with best clinical practice…” , whereas “…clinical research aims to 
establish what is the best clinical practice...” 43 
 
The primary function of clinical audit, which involves several professionals, is to 
improve patient care by evaluating healthcare professionals understanding of how 
they practice. A performance is reviewed to make sure that what should be done is 
being done. The outcome would either be that the process is satisfying or that 
improvements need to be commenced. A clinical audit is collaboratively and 
systematically and can be describe as a cycle where there are stages to be followed; 
First the problem or issue that needs to be reviewed is identified. Secondly,  criteria 
and standards relevant for the audit are defined. Thereafter the data collection is 
initiated and performance observed. Based on the data collection the 
performance/processes are compared with the standards and criteria. If the results 
are deviating from the criteria in a way that can not be approved, implementation of 
suggested changes is the final stage. The audit should be repeated a time after 
implementing the changes to see if improvements has succeeded, hence the process 
can be seen as an audit –loop. The purpose is to review the quality of care with an 
approach that is supportive and developmental to reach the goal of best services 






1.17 Project focus 
 
The focus of this project has been to analyse the documentation within the care plans 
written by the pharmacist at the General Medical ward at Glasgow Royal Infirmary. In 
order to do this analysis an existing categorisation system used at University of 
Strathclyde has been modified. A guideline for this modified system has also been 
developed, with the purpose of making future documentation easier and more 
standardised. This project is concentrating on secondary care delivery of 
pharmaceutical care but has been researching a tool, in form of a categorisation 
system that will have a goal of maintaining continuity of care with primary care 

































To compare two clinical settings in terms of the profile of pharmaceutical care 
delivered and the profile of medication use.  
To report the findings in ways that allow quantitative comparison of pharmaceutical 





1) Review the literature on major common diseases in acute general 
medicine/cardiology and diabetes during hospitalisation, and the clinical 
pharmacy documentation used in inpatients and at the point of discharge from 
hospital in Scotland. Review the literature on pharmaceutical care issue 
categorisation systems and the literature on introduction of non-medical 
prescribing in the UK. 
 
2) Describe the operational delivery of the clinical service using a process map 
that is validated by pharmacists involved in care delivery. 
 
3) Modify existing categorisation system used at University of Strathclyde to 
increase the robustness and clinical usefulness. Develop a guideline for use of 
the system. Test utility and validity of the modified system.  
 
4) Report on the care issues during a prospective survey phase of the study. 
Validate the clinical interpretation of the care issues. 
 




6) Apply data from the findings of a parallel survey of prescribing activity that 
aims to interpret the prescription turnover and quantify exposure of each 
patient to medication during their stay. 
 
 
7) Evaluate proposed templates of parameters of pharmaceutical care activity in 
order to report on their validity and utility for reporting care plans.  
 
8) Draw conclusions on the role of the audit findings in defining future application 
of non-medical (including pharmacist) prescribing. 
  
 
2.2 Subjects and setting 
 
The clinical setting for this project was the General Medical ward at Glasgow Royal 
Infirmary, Glasgow. This ward has one permanent clinical pharmacist, Mr. Carl 
Fenelon, who works 8.30 am to 12.30 pm Monday to Friday which may vary 
according to clinical need. The ward does not have any technicians as member of the 
staff.  Being a ward for male, it has 22 beds which all where mostly occupied during 
the collection period. There are two rooms for isolated patients. 
 
There were two incidents were the ward was closed, eight days all together due to an 
outbreak of vomiting and diarrhoea. During these periods there were no new patients 
admitted. The pharmacist did also go away for some days in February and patient 
during these days were not included in the survey either.  
 
Patient turnover during the period survey period of 13 weeks was 122. Being a 
general medical ward the patients coming here have a diversity of conditions and 
diseases they need treatment for. Cardiovascular disease, diabetes, cancer, alcohol 
problems/liver diseases and infections, were among those that were seen most 







This project was conducted in parallel with investigator KH and collaborator Chan 
Sue Li. The investigator and KH had the same aims and objectives but were 
collecting their data from different wards. MPharm student Chan Sue Li studied 
prescription turnover and quantification of exposure of each patient to medication 
during their stay at the General Medical ward.  
 
2.4 Ethical Approval. 
The study was considered to be audit in nature.  This was forwarded to the chair of 
the local Glasgow Royal Infirmary Ethics committee who agreed that it was audit and 
further ethical approval was unnecessary. The investigator maintained confidentiality 
by anonymising all the patient included at the hospital, before bringing the data out.  
  
 
2.5 Literature review 
 
The investigator started the information search by reading through government 
document on pharmaceutical care and medicines management in the UK. The book 
Pharmaceutical Care Practice – the Clinician’s Guide by Cipolle et.al has also been 
one of the main sources to both clinical pharmacy and drug therapy problems.  
A literature search was performed in order to review the documentation on 
pharmaceutical care, medicines management, diabetic mellitus and cardiovascular 
disease, chronic disease management and non-medical prescribing etc. 
Searches were performed in medical databases such as Medline and Embase for 
articles related to the different subjects by using predefined searching terms. (MesH 
terms) SIGN or NICE guidelines were also used. Reference list to published articles 
on relevant issues etc. was also examined and those references of interest searched 
for. Different web pages of pharmaceutical information such as the Pharmaceutical 
Journal, Royal Pharmaceutical Society of Great Britain etc. and Google were used to 
supplement the search for literature when necessary. The search was limited to 






2.6 Collecting data from the ward.  
 
The investigator started to collect care plans from patient admitted to the ward from 
the 12th of January 2007. A 100 patients were included in the survey by the 8th of 
March. Care delivery was recorded from admission date to patient discharged / 
transferred/died. For the purpose of this project the pharmaceutical care plans were 
collected and copied retrospectively at the hospital in the period January to April on 
the average of twice weekly. Attending ward rounds and discussing with the clinical 
pharmacist validated the clinical interpretation of the care issues. The investigator 
and the pharmacist subsequently went through the care plans in order to clear up 
things that were ambiguous and illegible.   
The discharge prescriptions data were also collected and together with the medicines 
listed in the care plans these latter data were given to the MPharm student, Chan 
Sue Li, to be used in her report of prescription turnover. 
 
 
2.7 Process Mapping  
 
In order to describe the operational delivery of the clinical service by the pharmacist 
at the hospital ward, process maps were produced by using the software program 
Microsoft Visio 2003.  
Process mapping is diagrammatic form that describes and presents processes. It 
displays geometrically the various tasks a certain process contains using different 
boxes. To obtain a process map it is essential to talk to and involve the people who 
perform the tasks 45 By observing and conducting a dialogue with the people 
responsible for the task in focus, one can get a detailed overview over the actions 
performed and a good description of the different processes. Hence this is a way to 
identify areas where processes can be improved. This is also a good way to get a 
clearly set out summary over different processes made in a clinical setting. 
The investigator spent several days, from November and during the data collection 
period (January to March) at the ward. Two process maps were produced by a 
combination of observing, when attending ward rounds, and talking to/interviewing 
the pharmacist. There was no Standard Operational Procedure (SOP) in use for this 
ward. 
One process map was made to describe the action and steps taken by the 
pharmacist from the admission of the patient and during his stay, and one process 
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map was made to describe the actions taken place when the patient is going to be 
discharged. Suggested process maps were made and thereafter validated by the 
pharmacist at the ward in order to get them correct. 
Shaped used in making the process maps are described below:  
 











Process, describes a process undertaken and represents a 





Predefined process, is a step where a sub-process is defined, 
the main process is defined elsewhere in the process map or in 




Decision, this shape indicates a point where the outcome of a 
decision dictates the next step. The decision is often answered 




Document, a step that describes a document being produced 
  




2.8 Review and modification of the existing Categorisation system  
  
At the beginning of this project, in November 2007, the investigator in cooperation with 
collaborator KH started to test out the existing categorisation system, used at the 
University of Strathclyde, by analysing some previous care plans given by LS. This system 
was developed to describe pharmaceutical care. This system categorises a care issue into 
a Check or Change category (Strand, McAnaw)7, a Drug Therapy Problem (Cipolle, 
Strand)5 and a Quality Assurance Descriptors (McAnaw, Hudson)17. The advantages of 
combining different categorisation systems into one triangularised system is that the 
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categories supplement and support each other, and therefore they capture different 
dimensions of the pharmaceutical care issues.  
 
A patient’s drug treatment can be regarded as a cyclical process, which 
encompasses the design, delivery and evaluation of the treatment plan according to 
expectations predefined by clinical standards. Figure 1 shows the pharmacist’s 
systematic role as a contribution to increase the quality of this cyclical process. At 
each step during the cycle the pharmacist (and other health care team members) is 
in a position to perform checks to confirm the quality of the delivery of the treatment 
plan. Whenever the checks reveal deviations from the expectations established in the 
plan, changes to the treatment or the treatment plan are proposed or executed. This 
process can be viewed as a feedback loop, where changes are integrated into the 
cycle. 
 















Figure 1 Pharmaceutical care model 
 
 
The sources for the existing categorisation system, used at the University of 
Strathclyde were Pharmaceutical care class notes from the University of 
Strathclyde”14 the article “The Changing Roles of Pharmacist In Society” 7 and a 
“Data collection form for MSC project” (Appendix 1). As a result of assessing this 
system and testing out the categorisation by using care plans, it was revealed that 
there were difficulties and inconsistencies in the interpretation of the different 
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categories. The investigators in Ayr were also using the same categorisation system 
to evaluate the documentation of the pharmacist’s work, and had the same opinions. 
All four investigators (MRR, ROH, KH and MBC) came then together over several 
meetings during the period January – April 2008 to evaluate and improve the 
categorisation system. The system was scrutinised and those categories which the 
researcher thought needed a modification were explained and exemplified. The 
purpose was to optimise the categorisation as a triangularised system. By increasing 
the robustness and clinical usefulness of the categorisation system the aim was to 
develop a documentation-tool to be applied in future clinical practice. 
 
During this period literature on drug therapy problems, categorisation and 
categorisation systems were also reviewed. In addition it was arranged research 
meetings were the investigators ideas were discussed with the supervisors SH and 
CF, and PhD student TD.  As a result of this, modification and new ideas were 
incorporated and implemented in the categorisation system. As the investigators 
realised how different they all comprehended the existing system and that part of the 
system was difficult to interpret when categorising care issues in practice, it was 
decided that a guideline needed to be developed so that the categorisation could be 
perform on the same basis, and the system could be easy to use. The 
results/outcomes of the modifications, specifications and exemplifications made were 
all presented in the guideline developed. Fellow investigator IL used the system to 
categorise care issues in her project. She gave feedback on the use and 
understanding of the guideline. Also supervisor SH gave feedback during this 
process. 
 
Using the developed guideline to analyse care issues from the collected care plans, 
tested the utility and validity of the modified categorisation system.  
 
2.9 Database tool 
 
The data from the handwritten care plans were analysed and keyed in a database 
made to fit this project. The database was modified in cooperation with researcher 
assistant Susan McKellar using Microsoft Access®. Since recommendation made by 
the pharmacist was not taken into account in the categorisation system, the 
investigators made a tick box in the database to capture all care issue where the 
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pharmacist had made a recommendation in the modified system. The 
recommendations could be related to both checks and changes. The primary reason 
for this was to intercept the recommendations that were not taken into account and 
thus only categorised as a check in the categorisation system. The changes resulting 
from the pharmacist making a contribution to the clinical assessment were also 
marked. 
 
It was made a tick box to mark interaction as well. The investigators thought it would 
be interesting to see how many care issues were concerning interactions; either as 
checked for, or changes made in drug therapy due to. As pharmacists have the 
specific knowledge to discover interaction there was a interest to see if there was an  
attach importance to this type of drug therapy problem in particular.  
The categorisation of the care issues was done within the database and hence eased 
the systematic approach to the categorisation. By using the database, combination of 
different categories was possible and the investigator could extract statistical analysis 
of the data easily by making the necessary queries to the database. Data from the 
database was transcribed to Excel for further statistical processing  
  
 
2.10 Inter-rater reliability and Cohen’s Kappa 
 
In order to test out the practical application of the modified categorisation system, 
Cohen’s Kappa statistic was used to analyse the inter-rater reliability.  
The investigators wanted to test out the consistency in categorisation and the hence 
the comprehension of the categorisation system by using the guideline developed.  
The inter-rater reliability was performed between the investigator and co-investigator 
KH. Fifty care issues were randomly picked from each ward and categorised by both 
investigators. A comparison was made using the method of inter-rater agreement and 
Cohen’s Kappa. 
 
The inter-rater agreement was tested in four part of the system, and therefore four 
Kappa were estimated. The first part was whether the care issue had been assigned 
the same main category, which is a ‘Check’, a ‘Change in Drug therapy Process’ or a 
‘Change in Drug Therapy’. The division to two types of different changes had 
modified the category of changes. The measurement of inter-rater agreement in 
these categories were therefore of particular interest, to see if this division was 
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applicable and used similarly. The next part was the agreement into the 
subcategories of the former main categories.   
The last two parts were the Quality Assurance Descriptors (QAD). All care issues in 
the modified system are assigned into the QAD ‘Time Perspective’, but only 
‘Changes in drug therapy’ are categorised into the QAD ‘Degree of Change’. The 
understanding of this part of the system and the consistency in categorising care 
issues into these subcategories were of specially interest. The subcategories of ‘Drug 
Therapy Problems’ were not tested since these were regarded well known and not 
modified. (Appendix 3) 
 
2.10.1 The Inter-rater reliability test 
 
The data were arranged in a matrix with one rater vertically and one rater 
horizontally.(ref) The investigators tested four different parts of the system. Both 3x3 
matrix and 16x16 matrix were produced. (Appendix 3) 
 
Table 4. Example of matrix used to calculate Cohen’s Kappa 
Investigator B 
  
Checks Changes in Drug Therapy Process 
Changes in Drug 
Therapy Total 
Checks 1.1 1.2 1.3 X1 
Changes in Drug 
Therapy Process 2.1 2.2 2.3 X2 
Changes in Drug 









Total Y1 Y2 Y3 N 
 
 The observed agreement between the raters is the sum of the cells where the raters 
agree;  1.1, 2.2, 3.3. 
 
Σ O = 1.1+2.2+3.3 
 
The total proportion of observed agreement PO was calculated as; ΣO / N 
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Since it will be expected some agreement in each square between the raters by 
chance, this is also calculated. 
 
Expected agreement in cell 1.1 by chance would be: 
Σ1.1 ec = (Y1 * X1) / N, and so on for cell 2.2 and 3.3. The sum of all these expected 
values would be the number of agreements expected by chance, Σe c. The proportion 
expected by chance, Pec for every category was calculated as; 
Pec = Σ ec / N 
 
 
The measure of overall agreement is Kappa κ, a value ranging between 0 and 1. A 
larger value indicates better reliability. Kappa is calculated from the proportions of 
observed agreement  and expected agreement by chance frequencies as follows;  
 










The standard error (SE) and confidence interval (CI) were also estimated. 
 











The 95 % confidence interval for the percentage of agreement was calculated as; 
 






κ =degree of agreement between the rater 
Po = proportion of relative observed agreement 
Pec= proportion of relative agreement expected by chance 
1    = maximum agreement among raters (ref) 
κ = degree of agreement between the rater 
Po = proportion of relative observed agreement 
Pec= proportion of relative agreement expected by chance 
1    = maximum agreement among raters 
N = total trials (ref) 
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2.11 Comparison of Patient Characteristics and Pharmaceutical care activity 
between two wards. 
 
 
The categorisation of care issues lead to comparison of pharmaceutical care activity, 
as well as patient characteristics, between the General Medical ward and the Care of 
the Elderly ward at Glasgow Royal Infirmary. Statistical comparison of the distribution 
of care issues across the care issue categories was undertaken by using Fischer’s 
exact test, two-tailed. Statistical significance was defined as p<0.05 and so a 95% 
confidence interval (CI) was calculated. The CI was calculated from standard errors 
and value of t (in this case 1.984 for n= 99; t tables). The calculations were prepared 
by using both Microsoft Exel® and GraphPad Software - QuickCals.47  
 
The two wards were also compared after applying data from the findings of the 
parallel survey of prescribing activity. This part of the project turned out to be smaller 
than first anticipated, due to other priorities, so the results and comments will only be 
briefly commented. 
 
2.12 Focus group   
 
A focus group could be defined as “a group of interacting individuals having some 
common interest or characteristics, brought together by a moderator, who uses the 
group and its interaction as a way to gain information about a specific or focused 
issue.” 48 
Focus group is an interview technique and provides an alternative method to collect 
data, from individual face-to-face interviews. The focus group typically consist of 6-10 
participants who are selected because they have certain common characteristics in 
common that relate to the topic of the focus group (e.g. clinical pharmacists working 
at hospital wards). The focus group give an insight to how a group of people think 
about a specific topic and is a way of evaluating an issue and promote solutions.  An 
important feature of focus group is the interaction between several participations and 
the results of a discussion where opinions arise on a chosen issue. Hence the data 
obtained from a focus group, in terms of issues raised and views expressed, are 
natural interactive processes. By having a group discussion where several opinions 
are express and views given on a topic, information on different participants’ attitudes 
are obtained. This group interaction can stimulate participants’ ideas that might not 
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have been revealed in individual interviews. The identification of solutions for both old 
and new problems brings a wider perspective on the issues discussed. Focus group 
is viewed as a qualitative research tool and the use of this application has increased 
in pharmacy practice and health service research the recent years. 48-50 
The four investigators ROH, MRR, KH and MBC worked together with the arranging 
of the focus group and were also the moderators. Invitations to participations were 
sent out and a power point presentation was made. The intention with this focus 
group was to get a feedback on the understanding and usefulness of both the 
categorisation system and the guidelines. The main focus was to evaluate the 
modified system with attached importance to the changes made within the Change 
category and the Quality Assurance Descriptors. Also opinions on the importance of 
marking checks and changes related to recommendations made by the pharmacist 
and interaction were desirable. Questions were made to each part of the system to 
clearly set out what feedback was necessary. The participants had been given the 
guidelines with examples of categorisation of care issues and the power point 
presentation on beforehand. 
 
The focus group was held at the Strathclyde Institute for Biomedical Science on the 
28th of April 2008. The four investigators KH, ROH, MRR and MBC presenting the 
categorisation system via the guidelines and the results from categorising care issues 
documented at different wards. The participants were pharmacists from Glasgow 
Royal Infirmary and Ayr Hospital, in addition to Professor and supervisor Steve 





















3.1 Literature review 
The literature search resulted in articles and studies about pharmaceutical care, 
medicines management, documentation, chronic disease management, diabetes 
mellitus and cardiovascular disease. As all these fields have expanded in recent 
years there was not a problem to find sources on these subjects. On the contrary the 
challenge was to find reliable sources and those most relevant. The medical 
databases Pubmed and Embase where mostly used, but also the National Health 
Service’s web pages. These latter were sources in particular for non-medical 
prescribing and clinical audit. The book “Pharmaceutical Care Practice – the 
clinician’s guide” by Cipolle et al. was one main source on drug therapy problems and 
clinical pharmacy. These subjects were however supplemented by relevant articles. 
The book “Practical statistics for medical research ” by Altman was an aid for the 
statistical analysis. 
 
3.2 Producing Process Maps 
 
The investigator spent several days during the survey period shadowing the 
pharmacist at the General Medical ward at Glasgow Royal Infirmary. By observing 
and interviewing the pharmacist the understanding of tasks and processes performed 
during ward rounds were described by the investigator in process maps. One map 
was made for the admission and patient’s stay, and one process map was made for 

















3.2.1 Process map Admission 
Pharmacist ward round
Check clinical notes
Check GP’s note/call GP
Commence care plan
 - Present of complaint 
 - Drug history
 - Medical history
 - Laboratory results
Add identified 





Is there a 
actual DTP?
Discuss with physician
Make decision/ changes in the 
drug therapy






Update care plan 

































Table 5.Descriptions in the Process Map – Admission and hospital stay 
Processes Descriptions  
 





In general the pharmacist starts with checking the 
clinical notes written by the nurses and/or physicians. 
The first task is to take the patient’s drug history. If any 
information is missing the pharmacist have to make sure 
that the important information about the patient is gained 
and added in the notes. This could be done by talking to 
either the nurses/physicians or calling the GP. Also 
talking to the patient can be clarifying enough. 
 
 





Information from the clinical notes /GP are written down 
in the pharmaceutical care plan in order to have an 
overview to identify the patient and do the assessment. 
 
Confirm medication profile with physician, 
GP and or /patient 
 
The information gained is confirmed and any 




Identify care issues and reveal 






This is an ongoing process, which is undertaken both for 
new patients and inpatients. By checking the kardex, 
monitoring every stage of drug therapy and talk to the 
patients / staff, the pharmacist is able to identify care 
issues and reveal and prevent any potential or actual 
drug therapy problems. Having the responsibilities of 
optimise the patients drug therapy, giving the patients 
education or instruction on how to use their medicines 
(e.g. an inhaler) and explaining why there are on 








The care issues identified are added into the care plan 
along with the following action taken and the final 
outcome. The pharmacist happens to document check 
and changes that he confirms is performed by other 
health care team members. The action taken depends 
on the care issues identified, but often involves 
monitoring lab values etc. and the patient’s reactions to 
the treatment in general.  
 
 
Discuss with physician. Make a 
decision/change in the drug therapy 
 
 
If the care issues lead to actual or potential drug therapy 
problems, which require a change in the drug therapy 
the pharmacist discuss this with the physician in order 
for a change to be made in the drug record. 
 
 





The care plan works as a quality assurance document 
and should follow the patient as long as he is at the 
ward and when transferred to another ward. The follow-
up comprises monitoring the commenced treatment and 
continuing to identify care issues and subsequently 
potential and actual drug therapy problems. In other 
words ensuring safe end effective treatment. 
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3.2.2 Process map – Discharge 
 















Potential drug therapy 
problems 
Contact staff at 



































Table 6. Descriptions in the Process Map – Discharge 
Processes Descriptions  
 




Many of the patients are transferred to 
another ward for continuing of care so this 
concerns those who are discharge home 
from this ward. Occasionally as part of 
discharge planning the community 
pharmacist is contacted, particularly if there 
are issues surrounding compliance packs in 
order to ensurechanges are made promptly.   
 
 







The physician prescribes the patient’s new 
medication(s) and the pharmacist 
subsequently checks doses and indications. 
Additional information is occasionally added 
such as medicines stopped and reasons for 
this. Also recommendations are 
occasionally made also such as additional 
monitoring etc. 
 Also here will identification of care issues 
and potential and actual drug therapy 
problems be screened fore. Any changes 
made are discussed with the physician 
before the discharge prescription is sent to 
the dispensary.  
 




The dispensary is calling the ward if 
discrepancies and hence potential drug 
therapy problems are revealed. A clarification 
is made and then the prescription is 


























3.3 Modifying the categorisation system 
 
Following are the results of the each step of modifications and adjustments made to 
the categorisation system. The complete results presented as a Guideline are to be 
found in Appendix 2 
 
Checks 
The ‘Check’ category and its subcategories were kept in the same way as presented 
in the ”Pharmaceutical care class notes from the University of Strathclyde” 14 and the 
article “The Changing Roles of Pharmacist In Society”.7 Thus compared to the sheets 
of description used at the University of Strathclyde (Appendix 1) the subcategory 
“Formulary adherence” was removed. 
 
Table 7.The categories of Checks 
Check Code 
Medication need inquiry MED 
Effectiveness inquiry EFF 
Safety inquiry SAFE 
Compliance inquiry COMP 
 
 
The Change category 
In the existing system all changes made in the care plan, whether they were related 
to the actions taken to prevent drug therapy problem indirectly (patient data handling, 
patient behaviour ) or action affecting drug therapy directly (treatment plan changes) 
were combined in one category.(see Table 8) This lead however to difficulties when 
categorising. The actions made to patient behaviour and patient data handling were 
often not necessarily changes, more often just action taken in order to prevent future 
changes from happening. E.g. up-dates of the patient’s drug record if patient got 
NSAID allergy in order to prevent a drug therapy problem from arising if patient were 
given NSAID. (which would lead to a change in drug therapy). The outcome of these 
types of actions were therefore difficult to predict and so a subsequent assignment of 






Table 8.The original Change category 7 
Action Change 
Patient behaviour 
 Patient expectations of treatment 
 Comprehension 
 Participation 
Patient data handling 
 Patient characteristics 
 History (indications, contraindications) 
 Continuity of care 
Treatment plan changes which address 
 Drug choice 
 Dose 
 Route, dose form 
 Dose interval / timing 
 Course duration 
 With added precautions/interactions 
 Stop drug pending review 
 
 
The pharmacist takes different actions to improve the pharmaceutical care of the 
patient. Not all of these actions result in a change in the patient’s drug therapy or 
have an outcome known to the pharmacist. Still it is important that these actions are 
quantified, as they are an important part of the pharmacist’s delivery of 
pharmaceutical care. 
 
The Change category was modified by dividing it into two categories of changes – 
‘Change in Drug Therapy Process’ and ‘Change in Drug Therapy’. It was considered 
necessary to distinguish between actions concerning the patient’s drug therapy and 
action regarded other pharmaceutical care needs of the patient.   
  
Table 9. Division of  the Change category into two; 
Changes in Drug Therapy Process Changes in Drug Therapy 
 
 Clinical (shared) record of patient 
characteristics 
 
 Drug selection (starting new or 
changing drug) 
 Clinical (shared) record of drug history  Dose 
 Continuity of information/care between 
clinical settings 
 Route/dose form 
 Level of patient monitoring  Dose interval/timing 
 Health care team member(s) 
information/education 
 Duration 
  Stop drug temporarily/ permanently 





Change in Drug Therapy Process 
The category ‘Change in Drug Therapy Process’ are changes in care process where 
the outcome is hard to determine or is too speculative to lead to a drug therapy 
problem. This category describes the actions the pharmacist performs to prevent 
potential drug therapy problems and to identify actual drug therapy problems. 
The wording of the subcategories were modified to enhance the comprehension of 
what they were concerning. 
 
Patient data handling 
 Patient characteristics 
 History (indications, contraindications) 
 Continuity of care 
 
This former subcategory was modified by transforming the wording into three new 
subcategories;  
 
 Clinical (shared) record of patient characteristics 
 Clinical (shared) record of drug history 
 Continuity of information/care between clinical settings 
 
The description of each of these are described in the guideline (in the Appendix 2) 
There was also added some new subcategories to the ‘Change in Drug therapy 
Process’;  
 Health care team member(s) information/education.  
 
The investigators regarded recommendation in form of information/ education 
provided by the pharmacist to other health care members as an important action to 
be documented. This was not captured in the existing system. Neither this 
subcategory can be assigned a drug therapy problem and is therefore rather a 
change in the care process given. 
 
 Level of patient monitoring was also added.  
 
The addition of this subcategory was a result of care issues identified in the care 
plans regarding a need to increase/improve monitoring. This monitoring had been 
initiated or advised by the pharmacist as an action made to prevent drug therapy 
problem and spot those care issues which could lead to actually drug therapy 
problems. 
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All these actions were regarded as important parts of the provision of pharmaceutical 
care, although they are neither checks or a changes.    
 
Change in Drug Therapy 
The ‘Change in Drug Therapy’ category includes changes related to drug therapy 









This former category was also one which were difficult to measure the outcome as 
having resulted in some kind of change. Although the pharmacist intention is to 
provide information and education so that a patient’s comprehension and 
participation enhances, it is difficult to confirm that this has happened. It was decided, 
however, that these subcategories should be transformed and renamed into ;      
 
 Patient or Carer Level of Education (Understanding/Compliance) 
 
This subcategory was now modified to more clearly defining the pharmacist action to 
attempt to enhance the patient’s comprehension and participation. Although not 
measurable in a definite outcome this category now concerns compliance and the 
pharmacist intention and effort in improving compliance .The subcategory can further 
be categorised into a ‘Drug Therapy Problem’ (Inappropriate compliance) and was 
therefore  regarded as a ‘Change in Drug Therapy’ due to this. 
Except from the addition of this latter modified category in to the category of ‘Change 
in Drug Therapy Problem’ the subcategory ; 
 
Treatment plan changes which address 
 Drug choice 
 Dose 
 Route, dose form 
 Dose interval / timing 
 Course duration 
 With added precautions/interactions 
 Stop drug pending review 
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was only modified to a lesser extent by changing the name to ‘Change in Drug 
Therapy Problem’  and specifying some of the terms. (table 10) 
 
 
Table 10. Adjustment made to the subcategory ‘Treatment plan changes which 
address’ 
Treatment plan changes which address Changes in Drug Therapy 
 Drug choice  Drug selection (starting new or 
changing drug) 
 Dose  Dose 
 Route, dose form  Route/dose form 
 Dose interval / timing  Dose interval/timing 
 Course duration  Duration 
 With added precautions/interactions  excluded 
 Stop drug pending review  Stop drug temporarily/ permanently 
 
Key: Italics = adjustments made
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Drug Therapy Problem 
The subcategories of ‘Drug Therapy Problems‘ were those defined in the book 
“Pharmaceutical Care Practice – The Clinician’s guide” by Cipolle et. al (ref)  
These were basically kept in their original way. Still, some adjustments were made by 
giving  more examples to the subcategories to include a broader range of care 
issues. In addition the common causes for each subcategory were modified to 
enhance the correlation between the heading of the DTP subcategories and the type 
of care issues included in them. An additional subcategory ‘Unclassified’ was added 
in order to categorise care issues where the change is not patient specific. For 
instance due to non-adherence with local formularies and with only cost-control 
implications, rather than medication safety or effectiveness. 
 
Table 11. Adjustments to the categories of Drug Therapy Problems 








Unnecessary drug therapy 
 
 There is no valid medical indication for the drug therapy 
at this time 
 Multiple drug products are being used for a condition 
that requires single drug therapy→ fewer drug 
therapies 
 The medical condition is more appropriately treated with 
nondrug therapy 
 Drug therapy is being taken to treat an avoidable 
adverse reaction associated with another medication 
 Drug abuse, alcohol use, or smoking is causing the 
problem 





Need for additional drug therapy  
 A medical condition requires the initiation of drug 
therapy 
 Preventive drug therapy is required to reduce the risk of 
developing a new condition 
 A medical condition requires additional 
pharmacotherapy to attain synergistic or additive effects 
 The duration of drug therapy is too short to 





Ineffective drug  
 The drug is not the most effective for the medical 
problem 
 The medical condition is refractory to the drug product 
 The dosage form of the product is inappropriate 
 The drug product is not an effective product for the 
indication being treated 
 The time of dosing or dosing interval is not the 
most effective 


















Dosage too low  
 The dose is too low to produce the desired effect 
response 
 The dosage interval is too infrequent to produce the 
desired response 
 A drug A drug-drug/food/lab/disease interaction 
reduce the amount of active drug available 
 The duration of drug therapy is too short too produce 







Adverse drug reaction  The drug product causes an undesirable reaction that is 
not dose-related 
 A safer drug product is required due to risk factors 
 A drug interaction →A pharmacodynamic drug-
drug/food/lab/disease interaction causes an 
undesirable reaction that is not dose-related 
 The dosage regimen was administered or changed too 
rapidly 
 The drug product causes an allergic reaction 
 The drug product is contraindicated due to risk factors 
 The time of dosing or the dosing interval is not the 
safest. 
 





Dosage too high  
 Dose is too high 
 The dosing frequency is too long 
 A drug interaction A drug-drug/food/lab/disease 
interaction occurs resulting in a toxic reaction to the 
drug product 








 The patient does not understand the instructions 
 The patient prefers not to take the medication 
 The patient forget to take the medication 
 The drug product is too expensive for the patient 
 The patient cannot swallow or self-administer the drug 
product available appropriately 
 The drug product is not available for the patient  




Unclassified ie. Non-DTP  
 Formulary adherence, e.g. generic switch 
 
Comment: 
The italics are those terms which were changed or deleted and the bold are those 
terms which were added. The modified version of ‘Drug Therapy Problems’ will be 








Quality Assurance Descriptors (QAD) 
This third category was the one which the investigators found challenging to 
categorise a care issue into since the meaning of the different terms were confusing 
and also the time aspects according to where they were applicable. There were a 
continuously modification of this part of the system in order to make it work in all 
aspects for both checks and changes. According to the existing system only checks 
were assigned the subcategories of verification, monitoring and confirmation. These 
terms were related to the Start of treatment, as treatment continues and after a 
period of a course of treatment, respectively.  
 
What was contemplated was the subcategories of Changes; adjustment, modification 
and review. According to the existing system both adjustment and modification could 
be done at the Start of treatment, and as treatment continues. By just signing a 
change the QAD of either adjustment or modification it was not specified where in the 
treatment cycle this change took place. In order to make this happen it was decided 
that each change also would be categorised into the QAD for its preceding check in 
order to give it a time aspect as well. 
Since now both Checks and Changes, that is “Change in Drug therapy Process” and 
“Change in Drug Therapy” all were categorised into the QAD for Check, to add a time 
perspective in the treatment cycle to the triangularised system, the QAD for Checks 
was renamed  QAD Time perspective. The QAD for Change was renamed Degree of 
Change since this subcategory now only described what extent of change in the 
category Change in Drug Therapy is made. 
 
Short summary of assigning a care issue into the modified categorisation 
system. 
The care issue identified is either a Check or a Change (the latter, a check leading to 
a Change). The care issue is assign a subcategory of either the Check or Changes 
depending on its concerning. If the care issue is a change it is either a “Change in 
Drug Therapy Process” or a “Change in Drug Therapy”. All care issues are 
categorised into the Quality Assurance descriptor “Time Perspective”. Only “Change 
in Drug Therapy” is further categorised into the Drug Therapy Problem category and 
the Quality Assurance Descriptor “Degree of change”. The following table will give an 
overview over the system and how far the care issues are categorised. 
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 Table 13. Combination of different categories to a care issue 
Care issue QAD – Time 
Perspective 
















































3.4 Ward characteristics and Pharmaceutical care profile of the General 
Medical Ward 
 
The total number of patients admitted to the General Medical Ward during this survey 
period was 122. The pharmacist only saw 100 patients (82.0%) and these were 
provided a care plan and included in the survey. These 100 patients were admitted 
between the 12th of January and the 8th of March and all were discharged by the 10th 
of April. The reasons why the pharmacist didn’t see all the 122 patients admitted 
during this period were that some were admitted and discharged at the weekends 
and that the pharmacist was absent for 8 days during the survey period without 
cover. 
 

























Length of Stay (days) 11.8 
(10.6) 
 
(9.7, 13.9) 8.0 
(5.0, 14.0) 
1-53 
Number of diagnoses 2.0 
(1.2) 


























(1.4, 2.1) 1.0 
(0.8, 2.0) 
0-11 





(0.1, 0.4) 0.0 
(0.0, 0.0) 
0-3 




(1.2, 1.9) 1.0 
(0.0, 2.0) 
0-9 




The table shows that the average age (SD) for the patients was 64.1 (14.2) years and 
that the range was quite broad, the youngest patient being 26 years and the oldest 
98 years. The range of length of stay is also broad ranging from 1- 53 days. This 
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gives a relative high mean (SD) of 11.8 (10.6) days and is caused mainly by three 
long-term patients. The median (IQR) of 8.0 (5.0,14.0) would be the most correct 
description of average length of stay. These numbers are explain by the fact that this 
is a General Medical ward were patients in all age groups and with different 
conditions are admitted. 
 
The total number of care issues documented for all 100 patients during the survey 
period was 359 with an average (SD) of 3.59 (3.2) care issues per patient. As seen 
from the table the range of care issues was between 0-17, which is a broad range 
and thus making the SD high. It needs to be emphasised that these number are not 
representative for the delivery of pharmaceutical care by the pharmacist. These 
numbers only represent what the pharmacist is actually documenting. Also the fact 
that only care issues with an outcome have been categorised and taken into this 
analysis needs to be considered. 51 care issues documented were not included due 
to unknown outcome. 
 
Care issues regarded as part of the standard procedure were neither included. In 
general this would for instance be taking or checking drug history, general checks for 



































Table 15. Patient characteristics of different parameters 
  Prevalence, % 





 59  
22 
17 











    Nursing home







Number of drug history sources   
0
1





Key CVD: cardiovascular disease, patient with one or more CVD diagnosis, counted as one 
DM: diabetes mellitus, type 1 or type 2: AF= Atrial fibrillation 
 
  
Table 16.Diagnosis included in the term CVD 51   
Cardiovascular disease (CVD) 
 
Cardiovascular accident 
Congestive cardiac failure 
Coronary artery disease 
Deep venous thrombosis 
Hypertension 
Ischemic heart disease (Myocardial Infarction, Angina 
Acute Coronary Syndrome) 
Paroxionous atrial fibrillation 
Peripheral vascular disease 
Pulmonary thrombosis 
 
Table 17. Prevalence of diagnosis (top 6) 
Diagnosis Percent (%) 
Ischemic heart disease (Myocardial Infarction, Angina, Acute Coronary Syndrome) 33 
Atrial fibrillation 22 
Diabetes Mellitus 17 




Key Percent of total patients 
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There was a total of 65 different diagnosis documented. The patients could represent 
with more than one diagnosis, that is one patient could have Ischemic heart disease, 
Atrial fibrillation and Diabetes Mellitus. They are however counted here as one 
diagnosis for each patient. 4 of the 100 patients had none diagnosis documented.  
The primary drug history source documented is clinical notes. This would be a clinical 
note written by nurses and /or physicians. The pharmacist has used notes for 95 of 
the 100 patients. In most instances the pharmacist has only documented the use of 
one drug history source. Five of the patient had no sources of drug history.  
 
 
3.5 Categories and distribution of Care Issues 
 
Table 18. Distributions of care issues into main categories 
Main categories Count  Percent % 
Checks 177 49.3 
Change in Drug Therapy Process 27   7.5 
Change in Drug Therapy 155 43.2 
Total 359 100 
 
This table shows the distribution of the total of 359 care issues documented. There 
were an almost even distribution between the ‘Checks’ 177(49.3%) and ‘Changes in 
Drug Therapy’155 (43.2%) while care issues categorised into the ‘Change in Drug 




Quality Assurance Perspective 
 
Table 19. Subcategories of the QAD Time Perspective according to type of care issue. 
QAD Time 
Perspective Checks(%)
 Change in DT 
Process (%) 
Change in Drug 













 113(31.5) 17(4.7) 92(25.6) 222(61.8) 
Confirmation 












Key Percent of total care issues 
 
All care issues are categorised into this QAD category so this reflects the distribution 
of the main categories of all care issues. As seen from this table, most of the care 
issues are monitoring (222(61.8%) and hence care issues documented during the 
patient’s treatment (during the delivery of the treatment plan). ‘Checks’ and ‘Change 
in Drug therapy’ are types of care issues which are documented most frequently 
during monitoring. 
 


























6(3.4) 35(19.8) 0(0.0) 41 (23.2) 
Safety inquiry 
  

















Key Percent of total Checks 
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This table shows that those ‘Checks’ most frequently documented are monitoring of 
‘Safety inquiry’ (during the patient’s treatment) and verification of ‘Medication needs’, 
(at the start of treatment) respectively. Of the total of 59  (33.3% ) checks being 
verification it can be seen that 39(66%) of these were ‘Medication Need’ inquiries. 
Most of the checks performed during the patient’s treatment (monitoring) were; 
‘Safety inquiry’, 60(33.9) and ‘Effectiveness inquiry’, 35(19.8).  
 
Few of the checks documented were ‘Compliance’ check 6 (3.4). There are also few 
documented checks categorised as ‘Confirmation’ 5(2.8%)  
 
 
Table 21. Distribution of subcategories of Change in Drug Therapy Process into 





CHANGE IN DRUG 
THERAPY 
PROCESS 
Verification (%) Monitoring (%) Confirmation (%) Total 
 









 2 (7.4) 
 






















































Key  Percent of total Change in Drug Therapy Process 
 
There is a relative even distribution among the different subcategories of the ‘Change 
in Drug therapy’ process but most process are regarding ‘Health care team 
information’ and ‘Level of patient monitoring’ (the pharmacist informing the staff to 
increase the frequency of monitoring). It is shown that most of these happen during 
the delivery of care, as monitoring. The pharmacist is also documenting action taken 
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in verifying clinical record of drug history. This could be a drug missing in kardex or 
drugs not prescribed on admission, which the patient is suppose to be on etc. 
 
Table 22.Distribution of subcategories of Change in Drug Therapy into subcategories  










































































































































Key:  Percent of total Change in Drug Therapy 
 
 
It can be seen from this table that the different subcategories of ‘Changes in drug 
Therapy’ mainly are distributed throughout the ‘verification’ and ‘monitoring’ 
subcategories. 
Most of the changes documented were made during the delivery of care (monitoring) 
in form of drugs ‘Stopped temporarily or permanently’. An example would be; a drug 
stopped temporarily due to a surgery, or permanently as no need for drug. The 
second most frequent change documented is ‘Drug selection (new or changing 
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drug)’at the start of treatment (verification), that is when the pharmacist first sees the 
patient or new treatment is started. Thus, Drug selection (new or changing drug) 
could be commenced during treatment, but being a new drug started this would be 
assign a verification since the pharmacist is verifying the need, and the dose and 
indication for this new treatment. Drugs recommence would be regarded as 
monitoring.  
 
‘Stop drug temporarily/ permanently ’ is also the only type of ‘Changes in drug 
Therapy’ that is categorised as a ‘Confirmation’. This would be those stop regarding 
antibiotic courses and other short term treatment (enoxaparin stopped when patient 
is mobile etc.) Also drugs stopped due to no indications, contraindications, 
interactions etc.  
 
The subcategory ‘Dose’ is also a quite frequently ‘Change in Drug Therapy’ and are 
typically a change related to monitoring of the patient’s treatment. 
A typically example of the subcategory, ‘Patient or Carer level of education 
(understanding/compliance)’ is education/ instructions given on warfarin, which 
typically are done twice at the start (verification) and during treatment (monitoring), to 
ensure that the patient have understood the information given
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Table 23. Distribution of care issues as counts (%) - in ‘Change in Drug Therapy’ into ‘Drug Therapy Problem categories 
   
DRUG THERAPY PROBLEM 
 
  

















Drug selection (starting new  
























































































































































Key ADR : Adverse drug reaction
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This table shows the relating ‘Drug Therapy Problem’ causing the most frequent 
‘Change in Drug Therapy’ (’Stop drug temporarily/permanently’ and ‘Drug selection 
(starting new or changing drug)’) . Within these subcategories most of the ‘Stop drug 
temporarily/permanently’ were due to the ‘Drug Therapy Problem’ ‘Adverse drug 
reaction 28 (18.1%) and ‘Unnecessary drug therapy’ 18 (11.6%).  
 
‘Need for additional drug therapy’ was the subcategory of ‘Drug Therapy Problems’ 
which were the primary reason for ‘Drug selection (starting new or changing drug)’. 
‘Dose’ was also among the most frequent care issues documented as a ‘Change in 
Drug Therapy’. The underlying ‘Drug Therapy Problem’s were ‘Dosage too low’ and 
‘Dosage’ too high respectively.  
 
‘Duration’ was a subcategory in ‘Change in Drug therapy’’ that no care issues were 
categorised into. There was neither no care issues categorised into the added ‘Drug 




Table 24. Distribution of subcategories of Change in Drug Therapy into subcategories 
of Degree of Change 
 




CHANGE IN DRUG THERAPY Adjustment (%) Modification(%) Review(%) Total 
 























































































Only the main category ‘Change in Drug Therapy’ is categorised into the QAD 
‘Degree of Change’. Most of the ‘Changes in Drug therapy’ are seen to be 
‘Adjustments’ related to drugs being stopped temporarily or permanently. Second is 
‘Adjustment’ made to changes concerning a new drug being commenced. Most are 
hence changes anticipated within the treatment plan and only 17(11)% of the 
‘Changes in Drug Therapy’ were modifications (meaning drug selection not 
anticipated and leading to a change in the patient’s treatment plan)  
None of the care issues were categorised as being a ‘Review’ of treatment, meaning 
reassessment of the patient’s treatment leading to a change in the expectations 
defined by clinical standards.  
 
 
Table 25. Time perspective linked to Degree of Change 
  
DEGREE OF CHANGE 
 














92(59.4) N/Ab N/Ab 92 
Confirmation 
 
N/Ab 16(10.3) 0(0.0) 16 
Total  132(85.2) 23(14.8) 0(0.0) 155(100)
 
 Key Percent of total Change in Drug Therapy; N/A = not applicable according to the Guideline 
 
As only ‘Change in Drug Therapy’ are categorised into the ‘QAD Degree of Change’ 
this table shows how extensive the ‘Change in Drug Therapy’ documented have 
been, and when in the patient’s treatment process the changes have been made. 
This numbers substantiate the findings in the previous tables and sum up that for 










Table 26. Recommendations made in main care issue categories 
Care issue category Count (%) 
Checks 
 
19 (12.7 %) 
Change in Drug Therapy Process 
 
9 (6.0 %) 
Change in Drug Therapy 122 (81.3 %) 
Total 150 (100.0 %) 
 
These numbers show that of all care issues documented (359) recommendation 
made by the pharmacist were involved in 150 (41.8%) of them. 
Of the total 150 recommendations, 122 (81.3%) were related to ‘Change in Drug 
therapy’. Recommendations made by the pharmacist but not taken into account by 





The investigators did also make a tick box in the database to track those care issues 
that dealt with interaction. Only 9 (2.5%)of the total 359 care issues were concerning 
interaction. 
 
3.6 Inter rater reliability test 
 
The investigators wanted to test out the consistency in categorising care issues and 
hence the comprehension and practical application of the modified categorisation 
system, by using the guideline developed. Cohen’s Kappa statistic was used to 
analyse the inter-rater reliability.  
There was an uneven distribution between some of the cells as there were no care 
issues in the subcategory ‘Review’ (‘QAD Degree of Change’). There were also quite 






There are no absolute definitions of the kappa values. The interpretation of the 
Kappa (κ) and with that, strength of agreement between the two investigators, was 
done by means of the literature 52 :  
 
 
Value of Kappa Strength of agreement 
< 0.20 Poor 
0.21 – 0.40 Fair 
0.41 – 0.60 Moderate 
0.61 – 0.80 Good 
0.81 – 1.00 Very Good 
 
 




























0.48 0.15 0.33 0.47 0.80 
κ 0.96 0.95 0.93 0.72 1.00 
SE(κ) 
 
0.019 0.023 0.041 0.067 0.0 
95 % CI 
 
0.94 - 1.02 0.91 – 1.00 0.85 – 1.01 0.58 – 0.85 - 
Strength of 
agreement Very good Very good Very good Good Very good 
 
Key Main Categories with subcategories. 
 
 
The matrix for the different categories and subcategories are found in  Appendix 3.  
The kappa for all categories ranged from 0.72 – 1.00 and this was interpreted as 
strength of agreement  ‘Good’ to ‘Very good’ for all categories.  
In the main categories the investigators only disagreed in one of the total of 100 care 
issues giving a κ (95 % CI) of  0.96 (0.94,1.00.) and strength of agreement ‘Very 
good’. 
 
When testing the inter rater reliability in the subcategories of all the main categories, 
the kappa within subcategories of ‘Change in Drug Therapy Process’ and  ‘Change in 
Drug Therapy’ were both found to be 1. The agreement in the subcategories of 
‘Check’ was also within the range ‘Very good’, but here the investigators disagreed 
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on 3 of the 100 care issues. This gave a κ (95 % CI) of 0.93 (0.85,1.00) within the 
subcategories of ‘Checks’ and a total κ (95 % CI) of 0.95 (0.90,1.00) for all the 
subcategories. 
 
The QAD ‘Time Perspective’ was the subcategory which had the poorest kappa, κ 
(CI) = 0.72 (0.59 – 0.85). Although the strength of agreement was ‘Good’ the lower 
value of the confidence interval for this kappa, 0.59, would be interpreted as 
‘Moderate’. The investigators disagreed in 15 of the 100 care issues in this 
subcategory. 
The strength of agreement in the last QAD subcategory ‘Degree of Change’ was 
‘Very Good’ and here the investigators did agree on all  26 care issues categorised 
into this subcategory. 
 
As all part of the modified system had a κ (CI) >0.60 (0.59, 1.00) this means that the 
strength of agreement between the two investigators in categorising care issues 
according to the guideline was satisfactory. Further comparison between the wards; 
General Medical and Care of the Elderly, of pharmaceutical care activity 



















3.7 Comparison of Patient Characteristics and Pharmaceutical care activity 
between two wards. 
 
Two ward, namely the General Medical ward (Ward A) and the Care of the Elderly 
Ward (Ward B), were compared in terms of the profile of pharmaceutical care 
delivered. The Care of the Elderly ward has one clinical pharmacist as member of the 
staff and the working hours are quite similar to that of the pharmacist at the General 
Medical ward.  







































p < 0.001 























1-14 p < 0.001 
 



















p < 0.001 
 








































p < 0.001 
 



















p < 0.001 
 




















p = 0.64 
 
Key  CI = 95% Confidence Interval;  IQR= Inter Quartile Range 
 
 
Comments to the table; 
The mean and median for almost all parameters compared are similar within both 
wards and this indicates a normal distribution and a suitable t-test was applied. 
Statistical significance was defined as p<0.05 and so a 95% confidence interval (CI) 
was calculated. The CI was calculated from standard errors and value of t (in this 
case 1.984 for n= 99; t tables).  
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There is a statistic significant difference in age between the two wards, where ward A 
has a mean age (CI) of  64.1 (61.2, 66.9) years and ward B has a mean (CI) age of 
80.9 (79.5, 82.3) years. This can be explain by the fact that ward B be is a Care of 
the Elderly Ward with age ranging from 82-98 years and ward A is a General Medical 
ward, with age ranging from 26-98 years.  
 
There is no statistical significant difference between the two wards in ‘Length of stay’. 
Both wards have a broad range in the length of stay and this is in both wards due to 
a few long-term patients. 
Number of diagnosis differs between ward A and ward B with the means (CI) 2.0 
(1.8, 2.3) and 4.2 (3.7, 4.6), respectively. The total care issues documented per 
patient differs significantly between the two wards; ward A has a mean (CI) of 3.6 
(3.0, 4.2) care issues and ward B has almost three time as many with its mean (CI) of 
9.7 (8.6, 10.8). This is further reflected in the category of ‘Checks’ where there also is 
a statistically significant difference between the wards; ward A has a mean (CI) of 1.8 
(1.4, 2.1) care issues and ward B has a mean (CI) of 6.4 (5.7, 7.1) care issues, which 
is more than three time as many as ward A. 
 
There is also a statistical difference in the mean (CI) of ‘Change in Drug therapy 
Process’ between ward A and ward B. The mean and median in this category differs 
substantially, and the data are probably not normal distributed.  
There was no statistical significant difference in the category of ‘Change in Drug 



















Table 29. Comparison of distribution of Pharmaceutical Care Issues into different 
subcategories 
 
WARD A  WARD B 
 
 
n % (95 % CI)  n 
% 
















p < 0.0001 
 
Medication need inquiry 
 
 
60 33.9 % 
(27.3, 41.2)  171 
26.7 % 




41 23.2 % 
(17.5, 29.9)  119 
18.6 % 




70 39.5 % 
(32.6, 46.9)  261 
40.8 % 




6 3.4 % 
(1.4, 7.4)  89 
13.9 % 
(11.4, 16.8) p < 0.0001 
Changes in Drug  
Therapy Processes  
27 7.5 % 
(5.2, 10.8)  188 
19.3 % 
(17.0, 22.0) p < 0.0001 
Clinical (shared) record of 
patient characteristics 
 
2 7.4 % 
(1.0, 24.5)  4 
2.1 % 
(0.6, 5.5) p = 0.1658 
Clinical (shared) record of 
drug history 
 
7 25.9 % 
(12.9, 44.9)  120 
63.8 % 
(56.7, 70.4) p = 0.0003 
Continuity of information/care 
between clinical settings 
 
4 14.8 % 
(5.3, 33.1)  42 
22.3 % 
(17.0, 28.8) p = 0.4595 
Level of patient monitoring 
 
 
6 22.2 % 
(10.3, 41.1)  19 
10.1 % 
(6.5, 15.3) p = 0.1000 
Health care team member(s) 
information/education 
 
8 29.6 % 
(15.7, 48.7)  3 
1.6 % 
(0.3, 4.8) p < 0.0001 
 
Changes in Drug Therapy 155 43.2 % (38.2, 48.4)  144 
14.8 % 
(12.7, 17.2) p < 0.0001 
Drug selection  
(starting new or changing drug) 
 
36 23.2% 
(17.2, 30.5)  31 
21.5% 
(15.6, 29.0) p = 0.7820 
Dose 26 16.8% 
(11.7, 23.5)  27 
18.8% 





(1.2, 7.5)  5 
3.5% 





(3.9, 12.4)  18 
12.5% 




0 0.0 % 
(0.0, 2.9)  0 
0.0 % 





(28.4, 43.3)  37 
25.7% 
(19.2, 33.4) p = 0.0792 




(9.5, 20.6)  26 
18.1% 
(12.6, 25.2) p = 0.4311 
 
Key: 95% CI ; 95% Confidence interval 
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Only significant differences between ward A and ward B will be commented. 
 
Main categories: 
Ward B had a higher proportion of both ‘Checks’ with a mean (95% CI) of 65.8% 
(62.8, 68.8) and ‘Changes in Drug Therapy Process’ with a mean (95% CI) of 19.3% 
(17.0, 22.0) compared to ward A (49.3% (44.2, 54.5) and 7.5% (5.2, 10.8), 
respectively. Ward A had on the contrary a higher proportion of ‘Changes in Drug 
Therapy’ compared to ward B the mean (CI) being 43.2% (38.2, 48.4) vs. 14.8% 





The proportion of ‘Compliance inquiry’ was four times higher in Ward B compared to 
Ward A.  
 
Subcategories Changes in Drug Therapy Processes: 
 
Ward A had a considerably higher proportion of ‘Health care team member 
information/education’ than ward B, with a mean (CI) of 29.6 % (15.7, 48.7) and 1.6% 
(0.3, 4.8) respectively.  Ward B on the other hand had a higher proportion of ‘Clinical 
(shared) record of drug history’ than ward A. The means (CI) were 63.8% (56.7, 70.4) 
and 25.9% (12.9, 44.9) respectively. 
 
 
Changes in Drug Therapy: 
 

















Table 30.Comparison of distribution of Pharmaceutical Care Issues into QAD 
 Ward A Ward B  

























 283 44.2 % 
(40.4, 48.1) 





 63 9.8 % 
(7.8, 12.4) 
p = 0.0018 
Total 177 100.0 %  640 100.0 %  
 















p = 0.0022 
Monitoring 
 
17 63.0 % 
(44.2, 78.5) 
 59 31.4 % 
(25.2, 38.3) 
p = 0.0022 
Confirmation 
 
0 0.0 % 
(0.0, 14.8) 
 0 0.0 % 
(0.0, 2.4) 
p = 1.0 
Total 27 100.0 %  188 100.0 %  
 
 















p < 0.0001 
Monitoring 
 
92 59.4 % 
(51.5, 66.8) 
 29 20.1 % 
(14.4, 27.5) 
p < 0.0001 
Confirmation 
 
16 10.3 % 
(6.4, 16.2) 
 6 4.2 % 
(1.7, 9.0) 
p = 0.0474 
















p = 0.3919 
Modification 
 
23 14.8 % 
(10.0, 21.4) 
 14 9.7 % 
(5.8, 15.8) 
p = 0.2192 
Review 
 
0 0.0 % 
(0.0, 2.9) 
 2 1.4 % 
(0.1, 5.2) 
p = 0.2311 
Total 155 100.0 %  144 100.0 %  
 
Key: 95% CI: 95% Confidence interval    
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The proportion of ‘verification’ is seen to be higher in ward B compared to ward A 
with a mean (CI) of 45.9% (42.1, 49.8) and 28.8% (26.8, 40.6), respectively. The 
proportion of the subcategory ‘confirmation’ is seen to be more than three times 
higher in ward B compared to ward A.  
Ward A has though a higher proportion of ‘monitoring’ with a mean (CI) of 63.8% 
(56.5, 70.6) compared to ward B with a mean (CI) of 44.2% (40.4, 48.1). 
 
 
Changes in Drug Therapy Processes 
 
Higher proportion of verification are seen in ward B and compared to ward A, means 
(CI) of 68.6% (61.7, 74.8) and 37.0% (21.5, 55.8), respectively 
As the proportion of verification almost differs by a twofold, so does the monitoring. 
Ward A has a higher proportion of monitoring in this subcategory compared to ward 
B, the mean (CI) being 63.0% (42.2, 78.5) and 31.4% (25.2, 38.3), respectively. 
   
 
Changes in Drug Therapy 
 
Ward B had a considerably higher proportion of ‘verification’ with a mean (CI) of 
75.7% (68.1, 82.0), compared to ward A with its mean (CI ) 30.3% (23.6, 38.0). 
 
Ward A had a substantially higher proportions of both ‘monitoring’ and ‘confirmation’ 
with means (CI) of 59.4% (51.5, 66.8), and 10.3% (6.4, 16.2) respectively, The values 
for ward B being  20.1% (14.4, 27.5) and 4.2% (1.7, 9.0) respectively. 
  
 
Degree of Change. 
 









3.8 Comparison of ward A and ward B after applying data from the findings of 
a parallel survey of prescribing activity. 
 
MPharm students Chan Sue Li and Amiruddin Bin Ahmad Ramly studied prescription 
turnover and quantification of exposure of each patient to medication during their stay 
as a separate project.  The prescribing activity and pharmaceutical care activity of the 
two wards; the General Medical ward (Ward A) and Care of the Elderly ward (Ward 
B) was compared. This part of the project turned out to be a smaller than first 
anticipated, due to other priorities, so the results will only be briefly commented 
 
Table 31.Prescription and Pharmaceutical care activity 

























































Prescriptions active daily 
(courses) 
8.8  9.1  











































Prescribing actions within the 
stay as a proportion of all 
actions 
41.0%  40.0%  
 

































Number of courses needed to 
monitor (courses/change) 6.6  4.6  
 
Key:  *Significantly different (p<0.05) 
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Table 32. Explanation of prescription parameter 
 
Prescription parameters Definition 
 
Total medicines courses per patient 
 
Number of medicines exposed to the patient 




The total exposure of medicines to the 
patients during their inpatient stay.  The sum 
of all course-days, where one is the number 
of medicines prescribed on a given day. 
 
Mean duration of prescription (days) 
 
Sum off all prescriptions divided by the total 
number of prescriptions 
 
Medicines courses at discharge 
 
Medicines courses at discharge are the sum 
of medicines on admission and new 
medicines commenced substracting the 
medicines discontiuated.   
 
Internal prescription turnover 
 
Internal prescription turnover describes the 
changes in prescription actions during the 
patient’s stay at the ward and is obtained by 
dividing the total courses of medicines 
commenced and discontinued during ward 
stay by the total course-days. 
 
Total prescription turnover 
 
Total prescription turnover is obtained by 
totaling up the courses of medicines on 
admission and medicines commenced and 
discontinued during stay, as well as courses 
on discharge and dividing the sum with the 
total course-days. 
 
Number of courses needed to monitor 
(courses/change) 
 
Number of changes per course monitored 
can be expressed as number of courses 
needed to monitor to affect one change. 
(Total medicines courses per patient/ 
Changes per patient) 
 
 
Note that not all parameter presented in Table 32. will be used in this comparison. 
Statistical significance was defined as p<0.05 with a 95% confidence interval (CI) 
The two wards were regarded statistical different if the mean of one ward where 
outside the range of the CI of the other ward. The table shows that only three of the 
prescribing parameter were significantly different between the two wards. These are 
the ‘Total medicines courses per patient’, ‘Total course-days’ and ‘Medicines courses 
at discharge’. The mean numbers of ‘Total medicines courses per patient’ was 11.9 
in ward A and 15.3 in ward B, while the mean numbers of ‘Total course-days’ were 
99.4 at ward A and 119.5 at ward B. ‘Medicines courses at discharge’ were 7.4 and 
9.0 in Ward A and ward B respectively. Ward B had thus higher values than ward A 
on all these parameters. 
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The ‘Total Prescription turnover’ on the two wards was non-significantly different, and 
this indicates that the number of changes in drug therapy per course-day per patient 
is similar in ward A and ward B. 
 
‘Mean duration of prescription’ was almost the same in the two wards; 7.0 days in 
ward A and 7.4 days in ward B. 
 
 
3.9 Results focus group 
 
The focus group was held at the Strathclyde Institute for Biomedical Science on the 
28th of April 2008. The participants were pharmacists from Glasgow Royal Infirmary 
and Ayr Hospital in addition to Professor Steve Hudson (see the table below).  
 
Table 33. Participants attending the Focus group 
Title  Initial 
Pharmacist Ayr Hospital KW 
Pharmacist and Clinical Supervisor Ayr Hospital GJ 
Pharmacist and Clinical Supervisor Glasgow Royal Infirmary LS 
Pharmacist and Project Supervisor Glasgow Royal Infirmary CF 






The participants had been given the guidelines with examples of categorisation of 
care issues and the power point presentation on beforehand.  
Questions had been made to get feedback on the changes made to the 
categorisation system and the results from the categorisation of care issues at the 
four investigators’ respective wards.  
 
Following are a general description on the outcome and feedback gain from the focus 
group. There were mostly a discussion around each of the main questions asked 
during the presentations, where the participants gave comments on each question to 
a lesser or greater extent.  
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The focus group had been recorded and retrospectively transcribed by the four 
investigators. The results will be presented around the main questions asked. 
 
3.9.1 The Guideline 
 
What your first impression of the guideline? 
 Is it readable? 
 Is it possible to use the system by reading the guideline? 
 
The general feedbacks from the pharmacists were that the guideline needed to be 
read several times in order to comprehend the whole system.  The categories of 
‘Checks’ and ‘Changes’ were comprehended easy but the Quality Assurance 
Descriptors were thought to be a bit complex. Comments on this part of the system 
were ; 
- “ I think the concept of time perspective is a little bit (…) unfocused. And I think the 
intention is that this has to do with a role in quality assurance and that the time 
perspective becomes a little bit secondary. Certainly when talking about changes it 
becomes even more vague..” 
- “ Some of the language you use, there are lots of words that could mean the same thing, 
but are taken to mean different things……. But if you are actually modifying or adjusting 
things, or confirming and verifying things, that means two different things(?) you would 
need to know what language to use in this context.” 
 
Care issue not categorised 
 
Comments from the participants after an explanation from the moderator of which 
care issues were not categorised; 
- ..”quite usually the pharmacist would write down things and not have the time to follow 
that up” 
 
Division of the change category into two 
 
Is it a logical division of the change category into two; ‘Change in Drug Therapy 
Process’ and ‘’Change in Drug Therapy? 
 
There was a discussion on whether some of the subcategories of the ‘Change in 
Drug therapy Process’ could be described as a change in ‘Change in Drug Therapy 
Process’. The subcategory discussed was the ‘Health team member 
information/education’, which was thought to be something outside the process and 
more of an action the pharmacist is involved in continuously. However it was 
emphasised by the moderators that in this system ‘Health team member 
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information/education’ information was linked to a patient related problem, and hence 
had to be patient specific to be categorised. The participants gave examples of 
different action taken among the pharmacist and type of information/ education 
provided. (e.g. notes to nurses on how to give I.V. infusions) The pharmacist at the 
Ayr hospital used an electronic prescribing system and would document this type of 
information in the care plans. Another pharmacist would only make a mark in the 
kardex, and therefore not document this type of action in the care plan. 
Comments that were made to the statement that giving information/ education to 
other health care members not were changes in process; 
 
- “it’s not a change in the drug therapy process, it is the drug therapy process……. It’s an 
activity, and a useful activity. So I’m just wondering if we should actually call these 
changes?  ” 
- “If we say changes in the environment of delivering drug therapy. Then that will satisfy 
the problem with it and it would also adequately describe the rest of them. ” 
- “A way of thinking about it as contribution to the drug therapy process.  ” 
- “So would that work then? Under the general heading of changes you’ve got 
contributions to drug therapy processes and changes in drug therapy.  
 
They all agreement was that this will still be classified under the overall changes. And 





The results from the categorisation were presented. First the four wards were 
presented with their distribution of ‘Checks’ into its subcategories. The distribution 
between the wards varied. 
 
Can similarities and differences be explained? 
 
The participants came with examples and explanations of what they thought were the 
reasons for the distribution of different types of checks at their respective ward. The 
agreement was that the different types of checks were cause by the nature of the 
ward; high proportions of ‘Compliance Inquiry’ at the geriatric ward was explained by 
patients here having a lot of polypharmacy. There was also comments on the number 
of checks; that these were probably not concurrent with the check actually performed. 
This was explained by the care plan not being a check list and that the pharmacists 
rather went through the checks mentally and performed them without spending the 
time writing them all down. Not all checks were routinely written down. 
There was agreed that documenting should be more consistence in future. 
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Change in Drug Therapy Process 
 
There were differences in the distribution into subcategories between the wards 
 
Can similarities and differences be explained? 
 
Some pharmacists explained that the reason for the difference in the ‘Clinical record 
of Drug history’ could be that at some of the wards the pharmacist were responsible 
for taking the drug history, but on other wards the pharmacists only used the clinical 
notes written by nurses/physicians. 
 
Comment to this;  
- ”It’s actually medical, legally one of the things that you would want to make sure was 
documented. It shows that you have all the information passed on.” 
 
 
Change in Drug therapy 
 
None of the four investigators had used the category ‘Duration’ when categorising 
the care issues into the subcategories of ‘Change in Drug therapy’. 
 
Is there a need for the subcategory ‘Duration’ to be a part of this category? 
 
Some of the participants were surprised that none care issues were categorised into 
this subcategory as they thought of duration of drug therapy as a common term. 
The investigators explained that they had categorised care issues concerning 
duration as stop drug temporarily/ permanently or start drug. 
There was agreed that the terms were overlapping as to whether the drug was 
stopped or the duration changed. It was suggested that the ‘Stop drug temporarily/ 
permanently’ would be the simplest and that the reasons for why a drug is stopped 
would be explained by the relating ‘Drug Therapy Problem’ category. 
 
Drug Therapy Problem 
 
In the modified system the investigators had added a category and named it 
‘Unclassified’ (i.e. Non-DTP - care issues regarding cost savings etc) However, very 
few of the documented care issues had been categorised into this category. 
 
Should the  category ‘Unclassified’ be a part of the system? 
Are these types of issues, regarded as pharmaceutical care issues? 
 
Comments: 
- "  I would say if someone is on a non-formulary drug that would be a care issue, and it’s 
something that we do spend time doing. So if you just loose it, you will be loosing parts 
of what the pharmacist does.” 
 
- “If you’ve got a category called ‘unclassified’ it would just be a bin, people would just put 
anything in it. So you are not sure what is put into there, and you would loose 




There was an agreement on these comments, and as the numbers were small for all 
the wards it was commented that this category did not give so much information in 
this aspect. The investigators explained that care issues regarding switch of dose 
form etc in most instances were classified as ineffective / not safest drug. This could 
however be due to an ambiguity by the way the care issues were documented. If they 
were not clearly documented as non-formulary drugs, the investigators might have 




Should interaction be part of the system? 
 
There was a an unanimity among the pharmacist that there was no point in having a 
own tick box for those care issues concerning an interaction. The argument was in 
general  that interaction was just one of many reason for why the pharmacist take 
action in changing drug therapy. The interaction is just an outcome of a care issue in 
the same way as ‘dose to high’, ‘dose too low’. The assumption was that interaction 
is not a bigger concern than making sure that the dose is correct, blood levels ok etc. 
Some of the pharmacist also state that they often went through a care issue 
regarding a interaction mentally and the only wrote down the result of the check or 
change made due to this, and not that it was an interaction originally. 
 
Recommendation 
Should recommendation be part of the system? 
 
The pharmacist did not see the importance of marking the changes and checks that 
were influenced by a recommendation made by the pharmacist. They argued that the 
recommendations in most instances lead to an discussion where the physician and 
the pharmacist most of the times came to consensus and this would be the 
succeeded check or change. One pharmacist did see that it could be useful 










Do these categories in general describe the pharmaceutical care delivered? 
 
There was a unanimity that the individual practice is various at the moment and that 
this system would contribute to documentation of problems. The guideline was 
though to be a basis for describing pharmaceutical activity, the pharmacists’ 
contribution to care. So far a potential tool for looking at different part of assessment.  
It was also commented that this categorisation system also would be useful for the 
pharmacist him/herself, to see where they put most of their effort, and by this be able 
to evaluate the reason for different distribution of the care issues documented (due to 
workload, or something not done often enough) and reconsider their prioritises.  
 
Quality Assurance Descriptors – Time perspective 
 
This part of the system were a bit confusing for all participants as they had different 
understanding of the terms; verification, monitoring and confirmation. In the guideline 
the terms are description of where in the patient’s treatment cycle a check or a 
change is performed. But the meaning of the words as individually descriptions of 
type of checks lead to a confusion since some of the pharmacists not familiar with 
using this system in their documentation, would say that a confirmation for instance 
could happen when the pharmacist first spoke to the patient. (this would be a 
verification according to the guideline) 
 
As the investigators in the modified system had categorised the changes according to 
their preceding check as well, in order to give the changes a time aspect in the 
treatment cycle, this lead to confusion about the terms. The participants had 
problems with assigning a change into categories which describes checks; 
verification, monitoring and confirmation. The pharmacists came with a suggestion to 
change the terms in order to capture the time aspect for both checks and changes. 
Comment;  
 - “ (...) if you say it happen at the design stage or the delivery stage or the evaluation stage. 
Could you do that? Then you avoid the duplication of using the same word (….) you still got 
the time perspective, you’re still following that…you just say design stages instead…” 
This was discussed thought of as a good solution to simplify a complex linking. 
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Quality Assurance Descriptors – Degree of Change 
 
Also in this category there were different opinions about the meanings of the 
subcategories adjustment, modification and review. The results from the 
categorisations showed that there were few ‘Review’ overall, and this surprised some 
of the participations. There were however revealed that the meaning of review in this 
context would be a re-assessment of the patient’s treatment and that it therefore did 
not happen too often at the wards where the patients often had a treatment plan. 
There were also discussions on what type of changes would be an adjustment and 
what would be a modification. The pharmacists did not all have a clear definition of 
this. 
 
The overall suggestion was to separate the changes into adjustment and modification 
made at the design stage, adjustment made at the delivery stage and modification 
and review made at the evaluation stage. This would then describe at which delivery 
stage the pharmacist is affecting a change. 
  
The discussion lead to the sum up that; The explanation for not using the ‘Review’ is 
that this type of change have to be prompted by the pharmacist and the doctor set 
the treatment goal. The pharmacist would probably have more influence on this type 
of change if he/her were attaining ward rounds with the physician, which few of the 
participants were doing in practice.   
 
Summary question 
Which potential uses you can think of for this system? 
Can you mention some positive and negative sides of the system? 
 
- “….pharmacist can benchmark their practice and see what they need to be working on. 
(..)  it makes you thinking about processes, it’s make you thinking about the patient 
actually going home and evaluating the outcome in another term. So there’s a lot of 
potential benefits” 
- “So that’s positive. The negative is that’s quit complex (…)I think that could potentially 
































































































4.1 Evaluating processes described in the Process Maps 
 
After evaluating the process maps, the observations made after shadowing the 
pharmacist and analysing care plans were also taken into consideration. It was 
obvious that the process maps are describing some of the general services the 
pharmacist ideally should provide for all the patients. The individual patients will 
however require different needs, extent of assessments and action to be taken. Thus, 
the pharmacist encounters diverse situations, and often needs to prioritise the time 
he spends at the ward.  
 
By assessing the patients’ medical needs and making an effort in identifying, 
resolving and preventing drug therapy problems, both the process maps have 
substantiated that the pharmacist is a contributor to the provision of pharmaceutical 
care.  
 
The investigator did not attend every ward round for all patients included in the 
survey and had therefore not seen every process taken for each patient. 
Nevertheless, the time spent shadowing the pharmacist did clearly show that 
documentation on the care plans did not coincide fully with actions actually 
performed. During this survey period of 13 weeks, 359 care issues had been 
documented .Based on this documentation it can be anticipated that the pharmacist 
has provided much lesser pharmaceutical care activity than the actuality. There are 
reasonable explanations for the pharmacist not being able not document every step 
taken. It needs to be emphasised here that the intention is not that the pharmacist 
should document every step taken in provision of patient care, cause that would lead 
to the pharmacist spending time on writing down action instead of performing them. 
Still, it is important that patient specific action taken in the treatment plan is 
documented to ensure safety and effectiveness for the patient, and also to improve 








4.2 The modified categorisation system  
 
The complete result of modifying the categorisation system is presented as the 
Guideline in Appendix 2. The reasons for the modifications of the different parts of 
the existing system have been presented in the results and are also justified to some 
degree in the Guideline. Following are a discussion on the modifications made in 
each part of the system and the experiences gained after testing the practical 
application of the categorisation system.  
 
4.2.1 Categorising care issues 
 
 
Different kinds of challenges occurred when applying the care issues from the care 
plans to the modified system. First of all, as the documentation on the care plans 
often were in the form of key-words and not systematised into the standardised lay-
out of a care issue; care issue – action – outcome, it was sometimes hard to 
capturing and interpret what all the care issue really concerned, and further 
categorising them. The documentation on the care plan was supposed to be cleared 
up by going through them with the pharmacist, but this was not completely fulfilled for 
all care plans. The care plans were discussed with the pharmacist to some degree 
and did clarify several aspects, but still there had to be made assumption by the 
investigator on some of the care issues. Secondly, the fact that the investigator was a 
student and due to that did not have enough clinical experience must also be taken 
into account when considering the clinical judgement needed to fully comprehend 
some of the situation. (This would typically be to assess whether a change would be 
an adjustment or a modification) A pharmacist documenting his/her own care issues 
by categorising would know the circumstances for the care issues, and what the 
investigators have had obstacles with would probably speak for it self and be more 
intuitively to the pharmacist.  
 
After scrutinising the system, making modifications and developing a guideline, the 
system was still thought to be a bit complex at some parts. All four investigators had 







The ‘Check’ category and its subcategories were not modified, as the applicability 
was thought to be good enough. There were no particular problems with the 
understanding and use of this category. 
 
Change in Drug Therapy Process 
 
The argumentations for dividing the existing change category into two have been 
explained in the results and guideline. The experience with this division when 
categorising, was that this was an applicable way of differentiate between changes 
related to drug therapy and prescription, and hence drug therapy problems, and 
those actions made to processes such as information to health care personnel, drug 
history and continuity of care. Common for the whole categorisation process were 
that some care issues did not fit perfectly to the alternatively subcategories of all 
categories and therefore had to be put into the one most obvious. An example here is 
the pharmacist offering smoking cessation to the patient. In those cases where the 
patient agreed to get help with smoking cessation this was considered a ‘Change in 
Drug Therapy Process’ as ‘Continuity of care between clinical settings’. But in those 
cases where the patient turned down the offer this care issue did not fit into any 
proper category. As no kind of change had been made this was categorised as a 
Compliance check, since this was considered as the closest one.  
 
When the existing system first was scrutinise the idea to separate some of the 
subcategories underneath the Change category was that the investigators though it 
was important to document the actions the pharmacist contributed with that where 
neither a check nor a change, which where the only options in the former system. As 
just ‘Action’ was assumed to be a diffuse description, the suggestion of describing 
these processes as ‘Change in Drug Therapy Processes’ came up. The purpose was 
to describe actions not regarded as drug therapy and drug therapy problem, but still 
important part of the pharmacist contributions in the patient care process.  
 
However, the term ‘Change in process’ was after categorising care issues and 
evaluating the system thought not to be the best description after all, as change is 
not the right description for all subcategories within this category. Many of the 
processes representing the subcategories cannot really be described as a change 
made. Like for instance ‘Health care members information’ and ‘Patient monitoring’. 
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These terms were among those discussed at the focus group. It was reach an 
general agreement that, for instance educating a nurse in how to give I.V is not a 
change in drug therapy process but rather a contribution to the drug therapy process. 
A reasonable suggestion to change the name of this category to ‘Contribution to Drug 
Therapy Process’ was made. 
 
Change in Drug Therapy and Drug Therapy problems 
 
These two categories had not been modified to the same extent as the former 
category and the following categories of Quality Assurance Descriptors.  In general 
assigning a care issue into a ‘Change in Drug Therapy’ and a subsequent category of 
‘Drug Therapy Problem’ category, were thought to be logically and quite intuitively. 
 
The subcategory ‘Duration’ as a ‘Change in Drug Therapy’ had not been used by any 
of the four investigators when categorising care issues, and after a discussion with 
the focus group it was suggested that this subcategory was unnecessary as one 
could use ‘Stop drug temporarily / permanently ’ or ‘Drug selection – start new or 
change’ instead. 
 
In the category ‘Drug Therapy Problem’ the investigators had added one category 
and named it ‘Unclassified’. The purpose with this was to handle those ‘Changes in 
drug Therapy’ that where not patient specific. (i.e. formulary adherence like generic 
switch due to cost control implications). After analysing the outcome of the 
categorisation it was shown that only a few care issue had been assigned into this 
category. Because many of the care issue only were written in the care plans as a 
switch of drug, most of them they were interpret to be due to ‘ineffective/not safest 
drug’. The investigators did not know the whole background for all the changes of 
drug, and therefore this category did not benefit. This ‘Unclassified’ category was 
also discussed at the focus group, and some of the pharmacist said that they spent a 
lot of time making sure that the patient where on the proper drug according to local 
formularies. Not regarding this a care issue and categorising it, would lead to 
information lost on what the pharmacist were doing. Still, renaming the category was 





Quality Assurance Descriptors 
 
Categorising care issues into the ‘Quality Assurance Descriptors’ categories lead to 
most of the speculations. First of all, although the different terms of these 
subcategories (verification, monitoring, confirmation and adjustment, modification) 
had been defined in the guideline they were not always intuitive when practical care 
issues were to be assigned into these subcategories. Since one not knew the whole 
aspect of all care issues this lead to problems in general with giving the care issues 
the right ‘Time Perspective’ as well as the ‘Degree of change’. Despite that a ‘Change 
in Drug Therapy’ had been made, one did not always know the extent of the change 
just by analysing the care plan.  
  
It was revealed at the focus group that the pharmacist working at different wards had 
different experience and understanding of the terms within the QAD subcategories as 
well. For some of them the terms ‘adjustment’ and ‘modification’ (‘Degree of Change’) 
had the same meaning and where difficult to differentiate between, although the care 
issue and its outcome were fully understood. This underline that these terms in 
general are difficult to use in this aspects as they are interchangeable and that a 
guideline with the explanation probably would be needed to perform the 
categorisation using these terms. Other had a clearer comprehension of adjustment 
and modification and used them to describe what changes they made. The same was 
the case with the ‘Time Perspective’ terms. There was an inconsistency between the 
pharmacists as what verification, monitoring and confirmation would be. The problem 
was that in this categorisation system these terms are a description of the time 
aspect in the treatment cycle, because they originally where QAD for checks. But as 
the meaning of the terms individually describe different types of checks there were 
confusion among some of the pharmacist since they argued that a ‘verification’ could 
happen during the treatment of the patient and not only necessarily at the start of 
treatment. This would apply to ‘confirmation’ as well. Some would say that they are 
‘confirming’ checks when they first see the patient and not only as an evaluation. The 
investigator had also experienced these inconsistencies when categorising, but had 
still followed the guideline and the definition made there.  
 
To be repeated; the investigators made a change in the existing categorisation 
system by renaming the QAD for ‘Checks’ to QAD –‘Time perspective’. All care 
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issues have been categorised into this category in order to capture the time aspect of 
when in the patient’s treatment the care issue was identified and acted upon. 
In the modified system this was practically carried out in the way that each ‘Change 
in Drug Therapy’ also was categorised into the QAD for its preceding check, as the 
QAD for ‘Check’ had a time perspective related to each of its subcategories 
(verification – beginning, monitoring- during treatment, confirmation - as treatment 
continues) But relating ‘Change in Drug Therapy’ to these term only to capture the 
time aspects has been realised to be too complex and confusing both by the 
investigators and the pharmacists at focus groups as well.  
 
 
4.3 Further improvements 
 
A solution for making the QAD more applicable has been discussed among the 
investigators and was also with the participants at the focus group. It has been 
realised that there is a need to make the terms in the QAD more specific by using a 
simpler and more neutral wording. The purpose with the QAD is to describe when in 
the treatment process the pharmacist is taking action and making his contribution to 
patient care (checks or changes), and also to capture the degree of changes made.  
Instead of talking about at the start-, during-, and as treatment continues, other more 
general descriptions of the treatment cycle can help the improvement. 
 
If this latter terms to describe the time aspect were renamed to stages in the 
treatment cycle; like design stage, delivery stage and evaluation stage, these could 
be applied neutrally to both checks and changes. It would be more reasonable to talk 
about an adjustment made in the delivery stage instead of  “in monitoring” which one 
needs to know means during treatment in this aspect. These terms would more likely 
fit better to all care issues as they are not a description of a type of check but neutral 
descriptions of stages in the treatment cycle; when in the cycle care issues are 








The delivery of pharmaceutical care to could then be described as follows;  
 
Changes in Drug Therapy 
1.Adjust an initial design 
2. Modify an initial design 
3. Adjust during delivery 
4. Modify after evaluation 





























Figure 2. Modified Pharmaceutical Care model 
 
The QAD categories would be better linked within the treatment circle and these 
categories would be less complex as both check and changes would fit into the 
general description of design stage, delivery stage and evaluation stage. 
Then the different ‘Degree of Change would be described as in the in the table; that 
is attached to each of the different stages and by describing a time aspect as well. 
The meaning of the different type of changes still needs to be interpreted and 
comprehended. But this circle indicates that an adjustment is a type of change made 
either at the initial design or during the delivery stage and is hence less 
comprehensive than a modifications, which also could be made at the initial design 
but often is a result of a change made after an evaluation.  
 
When it comes to the ‘Check’ category, it can be argued that its subcategories can be 
used interchangeable in the different stages of the treatment cycle. However as a 
pattern these subcategories in most instances fit with the time aspects they had. 
Getting familiar with these different definitions in the settings of categorising care 
issues, by using the guideline, are regarded as acceptable and applicable. The 
investigator has had the experience that these terms mostly are appropriate to use by 
the way they are defined in the guideline. 
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4.4 Amendment ahead and applicability of the categorisation system 
 
The intention with this system is good and the system has been shown to be 
applicable for practical use. It is however regarded to bee too complex to be used in 
everyday practice, as it is today, especially the QAD as they are not intuitively 
enough. In general both the categories for ‘Check’ and ‘Changes’ were regarded as 
easy and intuitive to categorise a defined care issue into. But the guideline has to be 
used to capture and use the whole triangularised system. The Quality Assurance 
Descriptors needs to be modified further, by changing the wording and specifying the 
link with time aspect.  This would make this part of the system more comprehensive 
and usable.   
 
In general it is thought that the different terms describing the documentation made, 
by categorising care issues, is an unfamiliar and new way of thinking for many 
pharmacist working clinically. To just present them this guideline and assume that 
they will start to document their care issues by categorising them would probably be 
to expect too much. Nevertheless, there is a potential of this system as a tool to aid 
future pharmacist in their documentation. Documenting problem solving is essential 
for the purpose of evaluating the work the pharmacists do as part of a hospital team 
on the wards. And by having a common system for documentation, it will be easier 
for the pharmacists to work within the same standards and for researcher to review 
and do research with their work. If further improvements are made to enhance the 
applicability and understanding of this categorisation system, it is believed that the 
system has the potential and could be implemented and presented in the curriculum 
for pharmacy students. In order to improve the lack of documentation by pharmacist 
today, it is essential that pharmacists learn and comprehend how to document early 
on, so that when starting to work clinically this is a naturally part the work at the ward. 
 
4.5 Inter rater reliability test 
 
The inter rater reliability test had been performed by picking 50 care issues from the 
two wards randomly. This gave an uneven distribution between the different 
categories as there were some categories not represented or too few of (e.g. 
‘Review’). The problem with this is that the value of kappa depends upon the 
proportions of prevalence in each category. Uneven proportions in the different 
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categories could be one reason why the Cohen’s kappa overall is so high, due to 
different ‘chance expected frequencies’. 52 
 
The investigators still thought that picking the care issues randomly was the best way 
to test the agreement in categorising care issues, instead of ensuring that all 
categories were represented. The testing of the comprehension and utility of the 
modified categorisation system would best be shown if the raters did not know that a 
certain number of care issues were supposed to be in a specific category. Despite 
the uneven distribution, Cohen’s Kappa is the best approach to indicate agreement 
between categorical interpretations.  
 
 
The results from the inter rater reliability test showed that the strength of agreement 
between the investigators was ‘Very good’ in all levels except from the ‘Time 
Perspective’ where the strength of agreement was ‘Good’. This could in addition to 
the facts explained above be due to close cooperation between the investigators 
during the survey period and development of the guideline. In general when 
categorising their own care issues the investigators discussed a lot how to interpret 
different care issue and which category a type of care issue should be assigned into. 
This former cooperation could have lead to a common interpretation, which could 
have resulted in a common categorisation pattern and also can explain the overall 
high kappa.  
 
It was however not surprisingly that the agreement was ‘Very Good’ in the main 
category because assigning a care issue into a ‘Check’, ‘Change in Drug Therapy 
Process’ or ‘Change in Drug Therapy’ does not require as much assessment and 
background information of the care issue as long as you have the action and 
outcome. 
 
The subcategories of the different main categories did also have a ‘very good ’ 
strength of agreement. The investigators had given each other relevant information 
on the care issues on beforehand, the type of info that would have been given by 
talking to the pharmacist who documented the care issues. Knowing the background 
for the care issues could be the reason why there were few disagreements in the 
subcategories. Within the subcategories there was only a disagreement in the 
subcategories of Checks (kappa (CI) =0.93 (0.85,1.00)). The subcategories of 
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‘Change in Drug Therapy Process’ and ‘Change in Drug Therapy’ had Cohen’s 
Kappa of 1. (Appendix 3). The strong kappa could indicate that between the 
investigators the comprehension and intuitive application of these two change 
categories were good. This is however biased by the fact that both the investigators 
have taken part in the modification and development of the guideline and discussed 
many of the care issues in general.  
 
The Quality Assurance Descriptors had been a part of the system which where 
thought to be complex and a bit confusing. In the QAD  ‘Time Perspective’ the kappa 
and hence strength of agreement were lowest (κ (CI) = 0.72 (0.59 – 0.85)). The 
raters had disagreed on 15 of the 100 care issue categorised into this category. The 
reasons for these disagreements were showed to be that the raters had made 
assumptions or misunderstood the setting of the those care issue which were 
unfamiliar, the background for the care issue had not been clear enough. An analysis 
showed that eight of the disagreements concerning ‘Time Perspective’ were ‘Checks’ 
and seven ‘Change in Drug Therapy’.   
 
The kappa of 1 in the QAD ‘Degree of Change’ was quite surprisingly as this had 
been one category causing difficulties to the investigators during the categorisation in 
general. One explanation could be the uneven distribution of care issues as 
explained above. In this category none of the care issues were ‘Review’ and 23 of 
the total of 26 care issues in this category were categorised as ‘Adjustment’ and only 
3 were ‘Modification’. Also knowing that this would be a difficult category could have 
led to giving too much information about the care issues to each other 
unintentionally. 
 
The inter rater test in this regard has shown that the two investigators had a common 
understanding of the categorisation system and due to this a comparison of 
distribution of care issues between the wards could be performed. To further test the 
comprehension and utility of the system in practice, an inter rater test between two 





4.6 Pharmaceutical care profile of the General Medical Ward 
 
The total number of care issues documented for all 100 patients during the survey 
period was 359 with an average (SD) of 3.59 (3.2) care issues per patient. This is as 
mention in the review of the process maps thought to be a misrepresentation of the 
care provided. A broad range 0-17 underline the impression that the pharmacist has 
had to prioritise his time spent on patients. 
 
Care issues considered as part of the standard procedure were not regarded as a 
care issue to be categorised. This would for instance be where the pharmacist have 
checked drug history and made a note about it, or sees that the patient got all 
medicines needed for an indication and this is fine. Only if these checks lead to a 
change or were out of the ordinary these would be identified as a care issues and 
categorised. The reason for this is that there would have been a lot of similar checks 
recurring, and this information would better be presented in the process maps and 
not as a part of the documentation system. 
 
 
4.7 Categories and distribution of Care Issues 
 
The ‘Checks’ were accounting for 177 (49.3%) of the care issues documented. These 
numbers are not surprisingly as checks are of great importance and comprises much 
of the tasks the pharmacist performs in order to ensure optimal drug therapy. These 
numbers might however be misleading according to the total checks actually made 
by the pharmacists, because as already explained, many of the checks are in general 
standard procedures and not regarded as care issues. The pharmacist may also 
perform routinely checks, which he does not write down although they might have 
concerned a care issue. This was the assumption the investigator had after 
shadowing the discussing with the pharmacist. 
 
The category “Change in Drug Therapy ” was the second most frequent type of care 
issues documented. This is reasonable since many of the checks (preceding) lead to 
a change in drug therapy. As opposed to the ‘Checks’ these numbers are more 
consistent with the changes the pharmacist actually has influenced (investigator 
observed when shadowing and confirmed by the pharmacist). There is however a 
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lack of totally changes documented (changes to enhance compliance is one 
example.) 
 
The category ‘Change in Drug Therapy Process’ was the smallest one as just 
27(7.5%) of the total number of 359 care issues documented was categorised into 
this category. This could be explained both by the fact the priorities of the pharmacist 
not are within this category or that these processes taken are not documented to the 
same extent as changes concerning drug therapy.  
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4.7.1 Subcategories of the QAD Time Perspective according to type of care issue 
 
 
The distribution of care issues into the subcategories of the QAD ‘Time Perspective’ 
showed that for all the main categories ‘monitoring’ were the major subcategory. This 
mean that common for all types of care issues is; they are mainly performed and 
documented during the patient’s treatment and delivery of the treatment plan. This is 
actually logical as these monitoring would typically with the purpose of ensuring safe 
and effective treatment. Examples would be checking that treatment is optimal by 
monitoring levels of digoxin and the like, blood pressure, liver function and kidney 
test (K+, Na+), estimating creatinine clearance, etc. 
 
Verification encompasses one third of the care issues. These are typical action taking 
place when the pharmacist first sees the patients and verification of the patient drug 
treatment is done, or when a new treatment/drug is started during the patient’s stay. 
This latter explains the high prevalence in verification regarding ‘Change in Drug 
therapy’.  
 
‘Confirmation’ only involved 21 (5.9%) of all care issue and were mainly related to 
Change in ‘Drug therapy’. As the patients at the General Medical ward often are 
admitted due to an acute exacerbation of a chronic disease or an acute episode of 
disease, ‘Confirmation’ in this aspects would in general be an evaluation of the 
patient’s treatment  to assure that expected effects are achieved (antibiotic course) 
adverse effects avoided (contraindication, interactions) etc. ‘Confirmations’ is a 
category that usually applies to care issues concerning the continuing evaluation of a 
chronic disease, an acute exacerbation of a chronic disease or an acute episode of 
disease. The continuing evaluation of a chronic disease would in most instances be 
done in the outpatient clinics.  
 
 
Distribution of subcategories of Checks into subcategories of Time Perspective  
 
Those ‘Checks’ most frequently documented were ‘Safety inquiry’ taking place during 
the patient’s treatment (monitoring) and verification of ‘Medication needs’, 
respectively. This is not surprising as continually monitoring of the patients drug 
treatment are of high importance and essential.   Also checking need for medication 
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is a task the pharmacist often does when he first sees the patients and during the 
patient’s treatment, to ensure that the patient is one the drugs needed and not on 
drugs unnecessary. 
 
Few of the checks documented were ‘Compliance inquiry’, 6 (3.4%). Those checks 
concerning compliance have thus been done in the start of treatment (verification) 
and would typically in this ward setting be the pharmacist offering the patient smoking 
cessation, checking inhaler technique, etc. If the pharmacist provided some kind of 
education or instruction this would be categorised as a ‘Change in Drug Therapy’ 
because it is related to the ‘Drug Therapy Problem’ ‘Inappropriate compliance’ There 
were also few documented ‘Checks’ categorised as ‘Confirmation’ 5(2.8%) and this 
can be explain by the fact that most checks are done at the beginning of the 
treatment  (verification) or during treatment (monitoring) and most confirmation would 
be related to changes made during treatment. 
 
Distribution of subcategories of Change in Drug Therapy Process into subcategories 
of Time Perspective.  
 
There was a quite even distribution between the care issues in this category. Those 
‘Changes in Drug Therapy Process’ documented were however mostly done during 
the patient’s treatment, (monitoring) and encompasses mainly ‘Health care team 
information’ and ‘Level of patient monitoring’.  Also verifying a drug history resulting 
in a correction, in the start of the patient’s treatment were among the frequently 
documented care issues in this category. These numbers could be explained both by 
the fact the priorities of the pharmacist are within these subcategories or that the 
changes in the other subcategories are just not documented to the same extent. 
 
Distribution of subcategories of Change in Drug Therapy into subcategories of Time 
Perspective  
 
The changes in ‘Change in Drug Therapy’ were mainly distributed throughout the 
‘monitoring’ and ‘verification’ subcategories, as ‘Stop drug temporarily/permanently’ 
and ‘Drug selection (new or changing drug)’, respectively. 
These most frequent ‘Changes in drug Therapy’ are related to the preceding checks, 
‘Medication Need inquiry and Safety checks’. These latter are one of the most 
frequently ‘Checks’, and the changes shows that many of these checks lead to either 
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a new drug being commenced or a drug stopped temporarily/ permanently due to no 
need for medication or stop due to safety concerns. 
 
Distribution of care issues in ‘Change in Drug Therapy’ into ‘Drug Therapy Problem 
categories. 
 
Those ‘Drug Therapy Problem’ causing the most frequent ‘Change in Drug Therapy’ 
(’Stop drug temporarily/permanently’) were ‘Adverse drug reaction 28 (18.1%), 
‘Unnecessary drug therapy’ 18 (11.6%). These numbers are substantiated by the 
literature facts implying that these are one of the most frequently drug therapy 
problems in general. 12  
 
All care issues in the changes regarding ‘Drug selection (starting new or changing 
drug)’ were caused by the ‘Drug Therapy Problems’; ‘Need for additional drug 
therapy’ except for one which was due to ‘Ineffective drug’. These numbers are not 
so surprisingly although the distribution is skewed. As there are clinical guidelines to 
be used for treatment in most instances, ineffective drug is in general not so frequent 
compared to patients actually being sub optimally treated.  
 
‘Duration’ was a subcategory in ‘Change in Drug therapy’’ that no care issues were 
categorised into. The reason could be the interpretation of the care issues by the 
investigator, since potential care issues for this subcategory was assumed to be 
‘starting new or changing drug’ or ‘stop drug’. There were neither no care issues 
categorised into the added ‘Drug Therapy Problem’ category ‘Unclassified’. The 
investigator did not find any documented care issue regarding this category (i.e. non- 
adherence with local formularies.)  
 
Distribution of subcategories of Change in Drug Therapy into subcategories of Degree 
of Change.  
 
Only the main category ‘Change in Drug Therapy’ is categorised into the QAD 
‘Degree of Change’.  
‘Adjustments’ constituted 132(85.2%) of all care issues categorises as a ‘Change in 
Drug Therapy’ and only 24 (14.8%) were categorised as ‘Modifications’. There were 
none care issues categorised as a ‘Review’. This means that most of the ‘Stop drug 
temporarily/ permanently’ and ‘Drug selection – new or changes’ which were caused 
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by ‘Adverse Drug Reaction’ and ‘Need for additional drug therapy’, respectively all 
mainly were adjustments. (an anticipated change within the treatment plan). 
As the QAD category was the one that the investigator have had most trouble with 
assigning the cares issues into, this could have affected the distribution. The 
guideline was followed to aid the interpretation of the care issues. Still, not having the 
whole background for all the care issues and not comprehend the fully assessment 
for all situation could have biased this outcome. 
 
The way the care issues were documented and the way that the investigator have 
interpret them could be the reason why none of the care issues were regarded as a 
review. This category would involve a re-assessment of the patient’s treatment and 
lead to a change in the expectations defined by clinical standards.  
 
 
4.7.2 Time perspective linked to Degree of Change  
 
The way of assigning the ’Change in Drug Therapy’ into the QAD ‘Time perspective’ 
(originally the QAD for ‘Checks’) was to add a time aspect to the changes. The 
numbers from (table 25) show that most of the ‘Changes’ are adjustment made 
during the delivery of the treatment plan to the patient (monitoring). These numbers 
are quite reasonable as it was seen that these types of actions were among those 




 Of the 359 care issues documented 150 were marked as resulting from a 
recommendation made by the pharmacist. Most of these recommendations were 
regarding ‘Changes in Drug Therapy ’ 122 (81.3%). However the investigators had 
also marked the ‘Checks’ that could be considered to have involved a 
recommendation from he pharmacist. This latter would in most cases be the 
pharmacist and the physician having a discussion and coming to an agreement.  
 
The investigator thinks that marking these care issues and thereby underlining the 
contribution to drug therapy is useful and interesting. The intention was to have a 
way to differentiate between the changes made due to the pharmacist input and 
those contributions made to check and changes in general. However marking these 
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recommendations would depend on the purpose with the documentation. If there is 
an interest to underpin how the pharmacist makes a value to the health care team, in 
one particular way, this could be useful. On the other hand, in every-day basis this 
could be argued to be unnecessary. These markings have just been a part of the 




The investigators did also make a tick box in the database to track those care issues 
that dealt with interaction. Only 9 (2.5%)of the total 359 care issues were concerning 
interaction. The same would apply here as for the recommendation. In this project 
there was an interest to see whether the pharmacist were paying particular interest in 
this type of drug therapy problem and therefore interactions were tracked. The 
pharmacist at the general medical ward did not document these in particular. And the 
number might be smaller than what actually is encounter as an interaction often is 





4.8 Comparison of Patient Characteristics and Pharmaceutical care activity 
between two wards. 
 
There was a difference in age between the two wards, ward A had a mean age (CI) 
of 64.1 (61.2, 66.9) years and ward B had a mean (CI) age of 80.9 (79.5, 82.3) years. 
This can be explained by the differences of the wards in general. Ward B is a Care of 
the Elderly Ward with an expecting high mean age, ranging from 82-98 years and 
ward A is a General Medical ward, with an diversity age –range, from 26-98 years.  
 
Care issues not categorised were different between the wards. These care issues 
would be care issues with unknown outcome. It was discovered that the pharmacist 
at ward B often wrote all care issues he was concerned about on beforehand and 
due to limit time did not cover them all. The difference can also be speculated to be 
differences in documentation, that is that either the outcome was not documented 
although it had an outcome, or that the care issues with no outcome was 
documented to a lesser extent between the two wards (that is when the pharmacist 
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documents care issues retrospectively he leaves out those care issues that did not 
result in an outcome).  
 
The relative big differences in number of care issues per patient are thought to be 
due to difference in documentation and not necessarily in the provision of 
pharmaceutical care activity. In general more checks are performed at ward B, being 
a Care of the Elderly ward, where poly-pharmacy has a higher prevalence compared 
to the General Medical ward. The difference in documentation of ‘Change in Drug 
Therapy Process’ with a higher mean at ward B can be explained by different degree 
of documentation in general, but also that more drug history inquiries are made at 
ward B.  As the numbers of ‘Change in Drug Therapy’ were statistically non 
significantly different these did not affect the difference in the total number of care 
issues per patient.  
 
 




Ward B had a higher proportion of both ‘Checks’ and ‘Changes in Drug Therapy 
Process compared to ward A . Ward A on the contrary had more ‘Changes in Drug 
Therapy’ compared to ward B. These differences might be due difference in degree 
of documentation rather than differences in actual work performed as both Checks 
and Changes in Drug Therapy Processes are categories the pharmacists admitted to 
omit to document (according to Focus Group). The fact that ward B had 972 care 
issues documented and ward A 359 care issues could also underpin this. The higher 
proportion of checks would be expected at ward B, as this is a Care of the Elderly 
ward and due to higher risk of adverse drug reactions and problems with compliance 











The proportion of ‘Compliance inquiry’ was higher in Ward B compared to Ward A.  
This is also reasonable as ward B is a Care of the Elderly ward. Compliance is 
known to be a greater problem with ageing, both due to reduced mental and physical 
function and to poly-pharmacy. 
 
Drug Therapy Processes. 
 
Ward A had in general very few care issues in this category, a total of 27 care issues 
compared to 188 care issue being a process change in ward B. 
 
Ward A had thus a higher proportion of processes regarding ‘Health care team 
member information/education’ than ward B. This difference can be explained by the 
different wards layout. Ward B is a long corridor where the patients are staying in 
different rooms. Ward A, the General Medical ward, is arranged as one big room with 
all patients together, and the kardex’ are to be found on each patient’s bed. This 
means that the pharmacist and other health care team members are in the same 
area at the same time and more interaction can take place without the pharmacist 
having to spend time looking for physician/nurses and vice verca.  
 
Ward B had a higher proportion of  ‘Clinical (shared) record of drug history’ compared 
to ward A. The difference could be due to the overall higher number of ‘Change in 
Drug Therapy Process’. But the investigators had also the impression, after 
shadowing the different pharmacists, that this difference could result from the clinical 
pharmacists’ time priorities. 
 
Drug Therapy. 
There were no statistical differences between the wards in these subcategories. This 
could imply that these changes are of priority to document for both pharmacists and 












The proportion of ‘verification’ and ‘confirmation’ were higher in ward B than A. 
Ward A had thus a higher proportion of ‘monitoring’. These results were expected 
after shadowing the pharmacists at both wards and can be explained mainly by 
different prioritising of documentation. More checks at ward B in general is what’s 
causing a higher proportion of both the verification and confirmation. While 
verification of ‘Checks’ would typically be made at the start of treatment, the 
proportion of confirmation on this ward would typically be confirming that drugs such 
as antibiotic and heparin had been stopped. 
 
Changes in Drug Therapy Processes 
 
In this category there was a higher proportion of verification in ward B compared to 
ward A. This could be explained by more changes needed due to lack of drug history 
at site B. Ward A had a higher proportion of monitoring in this subcategory compared 
to ward B. The contributing parameter here is most likely the higher number of care 




Ward B had a higher proportion of ‘verification’ compared to ward A, whereas ward A 
had higher proportions of both ‘monitoring’ and ‘confirmation’.  
‘Verification’ and ‘monitoring’ show here the same trends as under the checks. This is 
probably a result of the fact that when a high proportion of checks being made at 
different times this would lead to a corresponding high proportion of changes in drug 
therapy at the same time. 
 
Changes in Drug Therapy 
 
‘Changes in Drug Therapy’ being categorised as a ‘confirmation’ differs from the 
pattern of ‘Checks’. These could be du to the pharmacist at ward A having a more 
proactive role when it comes to stopping drug therapy and this could further be 
explained by the ward layout where the pharmacist more often run into the physician 
and can influence these changes faster. The pharmacist at ward A is also in more 
contact with the patient as the kardex’ are by the bedside and not in the corridor as in 
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Ward B. By dialoguing with the patients the pharmacist is able to reveal more the 
need of the patients and hence suggest stopping unnecessary drug therapy (pain, 




4.9 Comparison of ward A and ward B after applying data from the findings of 
a parallel survey of prescribing activity. 
 
Since this part of the project turned out to be given lesser prioriy than first expected, 
the findings here will only be commented briefly. 
The data from this comparison showed that only three of the prescribing parameter 
were significantly different between the two wards. ‘Total medicines courses per 
patient’, ‘Total course-days’ and ‘Medicines courses at discharge’ were all higher at 
ward B compared to ward A. The fact that ward B is a care of the Elderly Ward could 
explain these facts as there is a higher prevalence of poly-pharmacy in the elderly in 
general. The two settings were hence statistically different on all parameters 
regarding pharmaceutical care activity except changes in drug therapy. This can be 
explained by the differences in mean number of medicines courses prescribed during 
the stay, where more courses would require more checks by the pharmacist. 
 
 
4.10 Non- medical prescribing 
 
The analysis of the documented care issues on the care plans collected from the 
General Medical ward has revealed that the pharmacist is contributing to 
pharmaceutical care in several aspects. A total of 359 care issues had been 
documented.  As 155 (43.2%) of these concerned ‘Change in drug Therapy’ this 
shows that the pharmacist is actively taking part in assessing and making changes in 
the patient’s drug therapy. This contribution is underpinned by the fact that 122 
(81.3%) of the total 150 recommendations were categorised as ‘Change in Drug 
Therapy’. 
  
The results from the categorisations of care issues showed that many of the changes 
in ’Change in drug Therapy’ were regarding the choice of dosage, route form, 
frequencies, product and the like. These would be typically prescription changes, 
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which the pharmacist could have perform himself as he did the assessment that lead 
to the change made. The effectiveness of the pharmacist being a supplementary 
prescriber on this ward can be that unnecessary time spent by the physician on 
clerical which the pharmacist can do himself, can bee avoided. This would reduce the 
physicians’ workloads, freeing up their time to concentrate on patients with more 
complicated conditions and treatments.  
 
Although the findings from this audit cannot be generalised, they underpin some 
goals of supplementary prescribing already realised by the NHS. The hospital 
pharmacists have access to the patient’s clinical notes and are also in direct contact 
with the patient’s on daily basis. These are hence good reasons, in addition to those 




































For the time being pharmacists have not to a considerable extent undertaken the 
responsibility to document their provision to patient care and drug treatment. There 
has been a demand both from the NHS and others, that actions performed by 
pharmacists need to be recorded in order to develop and ensure the improvements in 
pharmaceutical care in Scotland.  
 
The focus of this project has been to analyse the documentation within the care plans 
written by the pharmacist at the General Medical ward at Glasgow Royal Infirmary.  
In order to do this analysis an existing categorisation system used at University of 
Strathclyde has been modified. A guideline for this modified system has also been 
developed and used in the categorisation process. A further evaluation of the system 
after testing the practical applicability and comprehension, and presenting it at a 
focus group, lead to proposals for additional improvements to enhance the 
usefulness and robustness. The intention with this categorisation tool is to make 
future documentation easier and more standardised. This could hence be an aid in 
maintaining continuity of care with primary care services after a patient’s discharge. 
  
The categorisation of care issues lead to a description of the pharmaceutical care 
activity provided by the pharmacist. Process maps were also produced to describe 
the operational delivery of the clinical pharmacy service at the ward. The overall 
evaluation of the processes taken by the pharmacist and analysis of the care plans 
lead to the assumption that care issues documented did not reflect the total care 
provided.   
 
A comparison of patient characteristics and provision of pharmaceutical care activity 
was also done. These results showed that both the type of care issues and 
documentations on care plans between the pharmacists of two wards were 
statistically different. Nevertheless, by assessing the patients’ medical needs and 
making an effort in identifying, resolving and preventing drug therapy problems, it has 








6.1 Appendix 1  
DATA COLLECTION SHEETS FOR MSC PROJECT 
 








Medication need inquiry 1 
Effectiveness inquiry 2 
Safety inquiry 3 
Compliance inquiry 4 
Formulary adherence inquiry 5 
 
CATEGORISATION OF CHECKS 
 








Patient comprehension  
Patient agreement  
and participation 
 
Patient characteristics  
Drug history  
Continuity of information/ 
care between clinical settings 
 
Drug selection  
Daily (total) dose increase  
Daily (total) dose decrease  
Route/dose form  
Dose interval/timing/duration  
Drug use precautions e.g. 
potential interactions 
 






CATEGORISATION OF CHANGES 
 
Type of change Code 
Modification MOD 
Adjustments ADJ 
Reviews (promt a review) REV 
 
 
CATEGORISATION OF DRUG THERAPY PROBLEMS (DTP) 
 
DTP Code 
Unnecessary drug therapy DTP1
Additional drug therapy needed DTP2
Inappropriate drug DTP3
Dosage too low DTP4
Adverse drug reaction DTP5





Starting new drug 
Change of drug 
Daily dose increased 



























6.2 Appendix 2 
 
 




Pharmaceutical care is delivered by a team of health care professionals. The focus of 
the categorisation system described here is pharmaceutical care contributions made 
by the pharmacist within that context.  
 
To better comprehend this guideline it is important to have an understanding of how 
the pharmacist provides pharmaceutical care. This is a cyclical process and will 
briefly be described here. 
 
The pharmacist initiates this process by gathering relevant information about the 
patient’s drug treatment and medical history, which reveals pharmaceutical care 
issues. The pharmacist handles the care issues by doing checks leading to three 
different results:  
 
1. The care issue is found not to be an actual or potential drug therapy problem 
that needs further follow up at this point. 
 
2. There is an identified need to take action(s) to prevent future drug therapy 
problems. 
 
3. A drug therapy problem is identified and there is a need for a change in the 




2 Definition of a pharmaceutical care issue 
 
A pharmaceutical care issue is an identified concern regarding a potential or actual 
drug therapy problem. A drug therapy problem is patient specific, and so does not 




3 The categorisation system – a short summary 
 
The categorisation system is developed to describe pharmaceutical care. This is 
done by analysing each care issue and assigning them into categories. This 
categorisation process provides a basis for quantitative description of the 
pharmacist’s contribution to pharmaceutical care, which makes it possible to 
compare pharmaceutical care provided by a pharmacy service across different 
settings. 
 
Each care issue is described according to a triangularised system which consists of 
multiple categories. The advantage of combining different categorisation systems into 
one triangularised system is that the categories supplement and support each other, 
and therefore they capture the different dimensions of the pharmaceutical care 
issues.  
 
Each care issue is categorised in three such dimensions; 
 
(1) As either a Check or a Change1; where a Change may be a Change in the Drug 
Therapy Process or a Change in Drug Therapy, depending on the outcome.  
 
The care issue is further categorised into 
 
(2) Quality Assurance (QA) Descriptors1, which indicate a care issue’s position in the 
process of delivering pharmaceutical care. If the care issue is a Change in Drug 
Therapy this category also describes the extent of the change made.  
 
The third dimension in the system is  
(3) Drug Therapy Problem2 and only a care issue identified as a Change in Drug 
Therapy will be categorised as such. 
 
If the outcome of the care issue is unknown, the care issue is incomplete and can not 
be categorised in the categorisation system.   
 
Table 1. Categorisation set-up 
Quality Assurance 
Descriptors 
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The different parts of the triangularised system with its categories are described 
below. 
 
4 ‘Check’ and ‘Change’ categories 
 
4.1 Checks  
 
When a care issue is identified, the pharmacist has to perform checks in order to 
detect required actions to prevent future drug therapy problems or required changes 
in drug therapy addressing actual drug therapy problems. If the check leads to 
neither an action nor a change the care issue is categorised as a Check. A care 
issue categorised as a Check is assigned to one of four subcategories; “medication 
needs”, “effectiveness”, “safety” or “compliance”, based on the reason for the inquiry 
as summarised in table 2.  
 
The pharmacist’s intentions behind making the check constitute the basis for the 
number of care issues identified and for the categorisation of the identified check(s). 
A check performed by a pharmacist may be an inquiry which addresses both 
effectiveness and safety, (for instance when INR or lying/standing blood pressure is 
measured). In that case the care issue will be divided into two care issues; one check 
of effectiveness and one check of safety.  
 
If the pharmacist recommends making a change in the patient’s drug therapy in order 
to resolve or prevent a drug therapy problem, but the responsible prescriber either 
doesn’t agree with the change or agrees but forgets to make it, the care issue will be 
categorised as a check because no change in the patient drug therapy is carried out. 
 
 





Medication need inquiry MED 
Effectiveness inquiry EFF 
Safety inquiry SAFE 




The category Change is divided into two types of subcategories; Change in Drug 
Therapy Process and Change in Drug Therapy. The Change in Drug Therapy 
Process category includes care issues relating to changes in the care process, and 
this means that the impact of the outcome often is hard to determine or is too 
speculative to lead to a Drug Therapy Problem category. The Change in Drug 
Therapy category, on the contrary, includes changes related to drug therapy, non-
compliance and prescription, where the outcome can be assigned a recognisable 
Drug Therapy Problem category. 
 
Even though all changes are inevitably the result of a check, such checks will not be 
categorised since their relevance is superseded by the resulting change. The care 
issue will be adequately described by the resulting categories of Change, Quality 
Assurance Descriptors and Drug Therapy Problem. 
 
5 Change in Drug Therapy Process 
 
The pharmacist performs different actions to address the pharmaceutical care needs 
of the patient. Not all of these actions result in a change to the patient’s drug therapy. 
Nevertheless it is important that these actions are quantified, as they comprise a 
great part of the pharmacist’s delivery of pharmaceutical care.  
 
The category Change in Drug Therapy Process describes the actions the pharmacist 
performs to prevent potential drug therapy problems and to identify actual drug 
therapy problems (Table 3).  
 
Table 3 Change in Drug Therapy Process categories 
Changes made to Code 
Clinical (shared) record of patient characteristics CHAR 
Clinical (shared) record of drug history DH 
Continuity of information/care between clinical settings CONT 
Level of patient monitoring MON 
Health care team member(s) information/education  INF 
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5.1 Explanations of the Change in Drug Therapy Process subcategories 
 
Clinical (shared) record of patient characteristics  
This and the next subcategory describe actions that may affect the patient’s drug 
therapy since his/her treatment is based on available patient information. For 
instance, it is important to note in the patient’s record if he/she is allergic to 
penicillins, in case an antibiotic treatment is required later.  These actions help to 
avoid potentially preventable drug therapy problems in the future.  
 
If the pharmacist corrects or up-dates the patient’s shared records, for instance adds 
two drugs that the patient is allergic to, this will be recognised as one care issue. If 
drug therapy changes have to be made as a result of the corrected or up-dated 
record, this is recognised as one care issue for each drug that is changed.  
 
Clinical (shared) record of drug history  
When the pharmacist takes the drug history, discovers errors in prescribing on 
admission and proposes/makes a change to the drug therapy based on this, this is 
interpreted as one pharmaceutical care issue for each drug that is changed.  
Continuity of information/care between clinical settings 
This subcategory encompasses the actions the pharmacist undertakes to ensure 
continuity of care and transfer of relevant information between clinical settings, 
including making new arrangements for the patient with other health care institutions.  
The clinical settings include all healthcare institutions that have responsibility for the 
patient’s health care.  
 
A number of care issues might be included globally in a document transferring the 
patient’s care between clinical settings. If the pharmacist prepares or advises on the 
document, but doesn’t follow-up on the recommendations made, that would be a 
single care issue. This is because the care issues have unknown outcomes, and 
therefore can’t be categorised. We can only categorise the action of the pharmacist 




Level of patient monitoring 
Some care issues can result in the identification of a need to increase/improve 
patient monitoring.  This increased/improved patient monitoring doesn’t have to be 
performed by the pharmacist, but he/she must initiate it or advice about it. 
 
Health care team member(s) education / information 
This subcategory describes care issues where the pharmacist contributes by 
providing information or education to other health care personnel regarding the 
patient’s drug therapy. 
 
6 Change in Drug Therapy 
 
A care issue that is categorised as a Change in Drug Therapy (Table 4) includes 
changes to;  
• the drug therapy of the patient 
• the patient/patient’s carer understanding of the drug therapy or disease  
• the patient’s adherence to their treatment plan, that is patient compliance   
 
Pharmacists, unless they are acting as prescribers themselves, will in most cases 
make a recommendation to the patient’s prescriber, and the care issue will be 
categorised as a Change in Drug Therapy if the recommendation is accepted and 
carried out.  
 
The outcome of changes made to the patient/carer understanding/compliance is hard 
to measure, but it is included in the Change in Drug Therapy subcategory because it 
can be categorised as a Drug Therapy Problem, and it can be viewed as a 














7 Drug Therapy Problems (DTP)  
 
The categories of Drug Therapy Problems are those defined in the book 
Pharmaceutical Care Practice – The Clinician’s Guide 2 by Cipolle et al. The 
categories are given examples here to include a broader range of care issues. In 
addition they are modified to enhance the correlation between the heading of the 
DTP subcategories and the type of care issues included in them. An additional 
subcategory Unclassified has been added in order to categorise care issues where 
the change is not patient specific. For instance due to non-adherence with local 
formularies and with only cost-control implications, rather than medication safety or 
effectiveness. 
 
Only Change in Drug Therapy types of care issue will be categorised into Drug 
Therapy Problem categories. The combination of the Change in Drug Therapy 
subcategory and the Drug Therapy Problem subcategory will describe the nature of 








Changes made to: Code 
Drug selection (starting new or changing drug) SEL 
Dose  DOSE 
Route/dose form FORM 
Dose interval/timing INT 
Duration DUR 
Stop drug temporarily/permanently STOP 
Patient or Carer Level of Education (Understanding/Compliance) EDU 
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Table 5. Categories and common causes of drug therapy problems 
Drug Therapy Problem        Common causes of drug therapy problems 
 

















There is no valid medical indication for the drug therapy at this 
time 
 
Multiple drug products are being used for a condition that requires 
fewer drug therapies 
 
The medical condition is more appropriately treated with non drug 
therapy 
 
Drug therapy is being taken to treat an avoidable adverse reaction 
associated with another medication 
 
Drug abuse, alcohol use, or smoking is causing the problem 
 
The duration of therapy is too long 
 











A medical condition requires the initiation of drug therapy 
 
Preventive drug therapy is required to reduce the risk of developing 
a new condition 
 
A medical condition requires additional pharmacotherapy to attain 
synergistic or additive effects 
 
The duration of drug therapy is too short to produce the desired 
response 
 












The drug is not the most effective for the medical problem 
 
The medical condition is refractory to the drug product 
 
The dosage form of the drug product is inappropriate 
 
The drug product is not an effective product for the indication being 
treated 
 
The time of dosing or dosing interval is not the most effective 
 
Route of administration is not the most effective 
 







The dose is too low to produce the desired response 
 
The dosage interval is too infrequent to produce the desired 
response 
 
A drug-drug/food/lab/disease interaction reduces the amount of 










Table 5 (cont.) Categories and common causes of drug therapy problems 



















The drug product causes an undesirable reaction that is not dose-
related 
 
A safer drug product is required due to risk factors 
 
A pharmacodynamic drug-drug/food/lab/disease interaction causes 
an undesirable reaction that is not dose-related  
 
The dosage regimen was changed too rapidly 
 
The drug product causes an allergic reaction 
 
The drug product is contraindicated due to risk factors 
 
The time of dosing or the dosing interval is not the safest. 
 
Route of administration is not the safest 
 









Dose is too high 
 
The dosing frequency is too short 
 
A drug-drug/food/lab/disease interaction occurs resulting in a toxic 
reaction to the drug product 
 


















The patient prefers not to take the medication 
 
The patient does not understand the instructions 
 
The patient forgets to take the medication 
 
The drug product is too expensive for the patient 
 
The patient cannot swallow or self-administer the drug product 
appropriately 
 
The drug product is not available for the patient 
 








8 Quality Assurance Descriptors 
 
A patient’s drug treatment can be regarded as a cyclical process, which 
encompasses the design, delivery and evaluation of the treatment plan according to 
expectations predefined by clinical standards. Figure 1 shows the pharmacist’s 
systematic role as a contribution to increase the quality of this cyclical process. At 
each step during the cycle the pharmacist (and other health care team members) is 
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in a position to perform checks to confirm the quality of the delivery of the treatment 
plan. Whenever the checks reveal deviations from the expectations established in the 
plan, changes to the treatment or the treatment plan are proposed or executed. This 
process can be viewed as a feedback loop, where changes are integrated into the 
cycle.  














Figure 1 Pharmaceutical care model  
 
The Quality Assurance (QA) Descriptors identify both the points in the feedback loop 
at which the care issues (the Checks or Changes) are implemented and the extent of 
changes in drug therapy. To emphasise what they describe, the subcategories for 
QA Descriptors are designated Time Perspective and Degree of Change. 
 
All care issues will be categorised according to the QA Descriptor Time Perspective. 
This QA Descriptor adds a time perspective in the treatment cycle to the 
triangularised system. If the care issue is a Change in Drug Therapy it will be 
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categorised according to the QA Descriptor Degree of Change as well. This QA 
Descriptor describes the extent of the change made (Table 6).  
 
Table 6. Summary of which care issues are categorised into the two different 
Quality Assurance Descriptors subcategories 
Quality Assurance Descriptors 
Time Perspective Degree of Change 
 
Check 
Change in Drug Therapy Process 
Change in Drug Therapy 
 
Change in Drug Therapy 
 
 
8.1 Time Perspective 
 
The subcategories of Time Perspective are Verification, Monitoring and Confirmation, 
see table 7.  These subcategories relate to the point in the system feedback loop 
where the initial check that identified the care issue was made. 
 
Table 7. Categorisation of checks according to quality system feedback loop 






medications in the 




Checks at the start of the treatment to make sure that, for 
each medicine, the patient: 
- is on the right medicine 
- is on the right dose 
- is not on unnecessary medication 
- doesn’t have any new needs for additional medication 
- is not receiving a combination of interacting 
medicines 
- understands how to take their medication and what it 






treatment is appropriate 






Checks as treatment continues which should ensure that, 
for each medicine, the patient: 
- is on receiving medication as intended 
- continues to be on the most suitable dose 
- has no symptoms of unwanted(adverse) effects 




Checking that medication 






Confirmation and documentation to identify that 
medication is: 
- resulting in expected effects on the patient's condition 
- not failing to control condition 




A ‘Verification’ is either done at the start of a new patient treatment or when the 
pharmacist first assesses the patient and the medication, see table 7. 
 
• In chronic disease management, for instance by a clinical pharmacist at an 
outpatient clinic or a community pharmacy, ‘Verification’ is done at the first 
episode of care with the pharmacist. That may or may not be at the start of the 
patient’s treatment but must be undertaken for the pharmacist to assure himself 
or herself that the proposed treatment plan is suitable for the patient’s need.  
 
• When the patient is seen in an interim episode of care interrupting chronic 
disease management, for instance by a clinical pharmacist at a hospital ward 
during an acute admission, the verification category will relate to when the 
pharmacist first saw the patient. ‘Verification’ of the patient’s drug treatment is 
done at admission, or when a new drug is started. All checks at this point in care 
should be categorised as ‘Verification’ even if the treatment has been going on for 




‘Monitoring’ is done during the patient’s treatment (during the delivery of the 
treatment plan) with the goal of assuring the medication process is being 
implemented as intended and within general expectations of signs of benefits 
and absence of adverse effects, see table 7. 
 
Confirmation  
‘Confirmation’ is an evaluation of the patient’s treatment to assure that expected 
effects are achieved, adverse effects avoided or suitably managed and that the 
condition is treated optimally, see table 7. This category usually applies to care 
issues concerning the continuing evaluation of a chronic disease, an acute 
exacerbation of a chronic disease, or an acute episode of disease 
 
8.2 Degree of Change 
 
The Degrees of Changes are Adjustment, Modification and Prompt a Review, see 
table 8. These three subcategories describe the extent of the change made. Both 
Adjustment and Modification may take place at the start or during treatment, while 
Prompting of a Review results from a failure in treatment and so only occurs after a 
trial period of treatment, see figure 1. 
 
Since it is difficult to distinguish between the extents of changes made in Change in 
Drug Therapy Process, only Change in Drug Therapy will be categorised into Degree 
of Change.  
 
Table 8. Categories of changes according to the extent of the change in the quality 
system feedback loop 
 
Degree of Change Code
Adjustment ADJ 
Modification MOD 
Review (prompt a review) REV 
 
If a Check leads to a Change, the Time Perspective (i.e. at what time in the treatment 
cycle the check is done) will influence the choice of the subsequent Degree of 
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Change. As seen in figure 1 and table 9, a Verification can lead to either an 
Adjustment or a Modification. A Monitoring issue can only lead to an Adjustment. 
If a need for a bigger change in the treatment is identified, a Confirmation of the 
whole treatment of the patient is needed before a decision to either ‘modify’ or 
‘review’ the treatment can be made. A Confirmation can lead to either a 
Modification or a Review, depending on the outcome of the ‘confirmation’. 
 
Table 9. Categories of changes according to the time aspect in the quality system 
feedback loop, linked to preceding check 
 
Time Perspective Code Degree of Associated Change 
Verification VER ADJ MOD 






Adjustment is defined as a recommended change to patient behaviour, treatment 
regimen or process of continuity of care that individualises pharmaceutical care 
within the agreed treatment plan. ‘Adjustments’ are anticipated within the 
protocol/clinical management plan, and the regimen is not markedly changed to an 
alternative treatment regimen. Most supplementary prescribing decisions made by 
pharmacists would probably fall into this category. 
 
Modification 
Modification is a change to the patient treatment that is not anticipated and leads to 
a change of the patient’s treatment plan.  
 
Prompt a Review    
A Review is a re-assessment of the patient’s treatment, and leads to a change in the 
expectations defined by clinical standards i.e. change in the expectations to the 
outcome of the treatment. Because the pharmacist is not able to review the treatment 
alone, but has to recommend a review to the patient’s main prescriber, the qualified 
term category is termed ‘Prompt a Review’. ‘Prompt a Review’ is done as a part of 
the evaluation of the patient’s treatment. This will be done more often in an outpatient 
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6.3 Appendix 3 
 
Matrix’ - Inter rater reliability test 
 
 
Table 34.Distribution of care issues used for inter-rater agreement 
 
Time Perspective  
 
Verification Monitoring Confirmation Total
Checks 26 34 3 63 
Changes in Drug Therapy Process 7 4 0 11 
Adjustment 6 17  23 
Modification 0  3 3 Changes in Drug Therapy  
Prompt a review   0 0 
  
  
Total 39 55 6 100 
 
 
Table 35.Main categories 





Checks Changes in Drug Therapy Process 
Changes in Drug 
Therapy Total 
Checks 63 1 0 64 
Changes in Drug 
Therapy Process 0 10 0 10 
Changes in Drug 
Therapy 0 0 26 26 
Investigator A 
Total 63 11 26 100 
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Table 36. QAD Time Perspective 
Investigator B 
  Verification Monitoring Conformation Total 
Verification 33 9 0 42 
Monitoring 3 49 0 52 
Confirmation 0 3 3 6 
Investigator A 






Table 37.QAD Degree of Change 
Investigator B 
  Adjustment Modification Review Total 
Adjustment 23 0 0 23 
Modification 0 3 0 3 
Review 0 0 0 0 
Investigator A 
















Table 38.Distribution of agreement within the subcategories of Checks 





MED EFF SAFE COMP TOTAL 
MED 18  2   20 
EFF 1 7    8 
SAFE   28   28 
Checks 
COMP       7 7 







Table 39.Distribution of observed agreement in all subcategories of the main categories 
 Investigator B 





  MED EFF SAFE COMP CHAR DH CONT MON INF SEL DOSE FORM INT DUR STOP EDU Total 
MED 18  2                 20 
EFF 1 7     1             9 
SAFE   28                 28 
Checks 
COMP       7                         7 
CHAR        0               0 
DH       6             6 
CONT        2            2 




INF                 2               2 
SEL            6        6 
DOSE             2       2 
FORM              1      1 
INT               7     7 
Changes in 
Drug Therapy 
DUR                0    0 
STOP                 4   4  
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